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Summary
Thyroliberin (TRH) has been shown in a number of laboratories to have 
behavioural effects in animals unconnected with its endocrine function. 
Pharmacological studies have suggested the involvement of dopaminergic 
neurones in some of the observed effects and cholinergic neurones in 
others. Many of the behavioural effects of TRH in rodents appear to 
originate in the nucleus accumbens and septum brain regions. In this 
thesis the effects of TRH, one of its metabolites (cyclo HisPro) and a 
TRH-analogue (CG3?03) on the release of dopamine and acetylcholine from 
rat brain tissue preparations were investigated,
TRH (l0"^-10"^M) stimulated the release of (^H)-dopamine from tissue-cube 
and P2 preparations of rat nucleus accumbens and striatum in a manner 
sensitive to the pH (pH 6.5 D>pH7.4) and composition of the incubation 
medium.
Gyclo-HisPro (imM) stimulated the release of ( H)-dopamine from P2
preparations of nucleus accumbens and striatum at pH 6.5 but appeared to
be no more potent than TRH in its effects.
GG3703 (10” 1^0""^ M) stimulated the release of (^H)-dopamine from tissue
cubes of rat nucleus accumbens at pH 6,5 but not at pH 7.4,
Neither TRH nor its analogues (O.ImM) had any consistent effect on the
o o '
release of (H)-acetylcholine or (H)-choline from tissue cubes of nucleus 
accumbens or septum at pH 7.4.
50mM-KGl in all cases stimulated the release of (H)-dopamine from tissue
preparations of nucleus accumbens and striatum at pH 6.5 and 7.4 and of
3 3both ( H)-acetylcholine and ( H)-choline from nucleus accumbens and septum.
These results suggest that the stimulation of release of dopamine by TRH
arise from a direct interaction of the peptide with dopaminergic neurones,
not ly a modulation of dopamine release caused by TRH affecting release of
acetylcholine. The increased potency of cycloHisPro and GG3703 relative to
TRH in behavioural paradigms may result from their resistance to degradation.
INTRODUCTION
1.1 Discovery and Identification of TRH
Thyrotropin-Releasing Hormone (TRH, Thyroliberin) is a tripeptide 
with the structure shown in Figure 1. This peptide was first 
isolated and purified from extracts of sheep hypothalamus 
(Burgus etal, 1969; Guillemin, 1978). It was the comparison 
between the mass - and infra-red-spectra of isolated TRH with the 
spectra of other peptides of known structure which led to the 
determination of the structure of this peptide (Fleischer etal,
1970). It was later shown that TRH isolated from porcine 
hypothalamus was identical to that of ovine origin. (Sçhally 
etal, 1969» Nair etal 1970).
Although the end-groups of TRH (pyroglutamate at the N-terminal 
and prolineamide at the G-terminal) are structures not commonly 
found in peptides and proteins, they are not unique to this 
hormone and occur in other peptides which have been isolated from 
the brain, as shown in Table 1. Table 1 lists some of the peptides 
found in mammalian brain which have been shown to affect neuronal 
activity and have therefore been grouped together functionally as 
neuroactive peptides (Hughes, 1978; Iversen, 1979» Burgen etal, 
1980). This list is not exhaustive since newly-discovered peptides 
are constantly being added to the group (Tatemoto etal, 1982; 
Unsworth etal, 1982),
Chemically synthesised TRH has been shown to have hypophysiotropic 
effects indistinguishable from the natural product (Fleischer etal 
1970). This introduction describes what is presently known of the 
biochemistry and neuropharmacology of TRH in hypothalamic and 
extrahypothalamic mammalian brain.
NH
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Figure 1; Structure of TRH

Table 1 Primary Structures of Known Neuroactive Peptides
Peptide 
K et-enkepha tin 
Leu-enkephalin 
^-endorphin 
Substance P 
Angiotensin II 
Corticotropin (aGTH) 
Lulib'^rin (PH.RH) 
Oxytocin
Vasopior^pn (4DH)
Thyroli bar in (TRH)
Kelanostatin (HIF)
Vasoactive Intestinal 
Polypeptide (viP)
Bombesin
Cholecystokinin-like
peptide
Carnosine
Neurotensin
Somatostatin
S tru c tu re
XGGFM
XGGFL
XGGFMTSEKSQl’FLVl’LFKNAI VQNAHKKG Q 
RPKPQQFFGLk-NHg 
DRVXIHPF-NH^ 
SXSIvIEHFRXGKPVGKKRRPVK\aPDGAEAELAEAFPLEF
pEHWSXGLRPG-NH^
CXIQNCPLG-NH
Ls-sJ
CXFQNCPRG-NH^
U-s-l
pEHP-NHg
PLG-NHg
HSD AVFlbNXTRLRK QJWKKXLNSILN-NH^
pEQRLGNQWAVGHLNi-NH^
NXMGTOF-NHg
AH
pELXENKPRRPXIL
AGCKNFFWKTFTSG 
L— S-S------- 1
Table 2 t Key to Amino Acid Symbols Used in Table 1
Symbol Meaning
A Alanine
R Arginine
N Asparagine
D Aspartic Acid
C Cysteine
Q Glutamine
■ E Glutamic Acid
G Glycine
H Histidine
I Isoleucine
L Leucine
K Lysine
M Methionine
F Phenylalanine
P Proline
8 Serine
T Threonine
W Tryptophan
X Tyrosine
V Valine
pE pyroGlutamlc Acid
-NHg amide G-terminal
—8—8— disulphide bridge
1.2 Hypothalamic TRH
The highest concentrations of TRH in the brain are found within 
the hypothalamus, in particular in the median eminence and the 
nucleus ventromedialis pars medialis. (Brownstein etal 197^! 
Jackson and Reichlin 197^). These loci presumably contain 
perikarjfa of cells which form part of the parvocellular system, 
which secretes hormones into the hypothalamic capillary bed of 
the hypothalamic-hypophysial portal system. (Maddrell and 
Nordmann 1979). See Figure 2.
Little is known of the metabolism of TRH in these neurosecretory 
cells but, assuming that these cells are similar to other 
characterised neuro-secretory cells in the hypothalamus, the 
following may be an outline of the processes involved;
1.2,1 Biosynthesis
TRH biosynthesis takes place in the perikarya of the secretory 
cells and the peptide, either as a precursor or in its mature form 
is "packaged” in membrane-surrounded vesicles or secretory granules. 
Although the precise synthetic route is as yet uncertain, 
formation of TRH-like immunoreactivity in horaogenates of 
hypothalamus has been observed in the presence of protein synthesis 
inhibitors (Reichlin et al 197^) . This discovery rules out 
synthesis of TRH as a discrete peptide via transcription and 
translation of a single short gene but does not preclude continuing 
synthesis by enzymic processing of an already-translated precursor 
peptide in a manner similar to vasopressin synthesis (Hughes 1978), 
nor biosynthesis by the action of a "TRH synthetase", analogous 
to the route of glutathione synthesis (Mitnick and Reichlin 1972).
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Once synthesised, the pre-secretory form of TRH must enter the
lumen of the smooth endoplasmic reticulum, to he transported to
the Golgi apparatus and packaged into secretory granules.
Processing for the production of the mature active peptide may
occur at one or more of these steps (Maddrell and Nordmann 1979)•
Secretory granules or vesicles, formed within the perikaryon
must be transported along the axon to the site of release. Such
transport is shown to occur by ligation or sectioning of the
axons of neurosecretory cells, which results in an increased
hormone concentration on the side of the cut or tie proximal to
the perikaryon. Studies with the electron microscope have
suggested the involvement of microtubules in the transport of
secretory granules,
1.2.2 Release
TRH release into the hypothalamic-hypophysial portal system
2+appears to be dependent on the presence of Ga ions but the 
exact mechanism has not yet been elucidated. Entry into the 
portal system lumen may take place through thinned or 
"fenestrated" patches of epithelium as is the case for vasopressin 
and oxytocin in the neurohypophysis. It has, however, not yet 
been shown that such fenestrations occur in portal capillaries. 
There is evidence that TRH is transported out of the median 
eminence and into the ventricular system. Tanycytes in the 
interface between the two systems have been implicated in this 
transport (Reichlin et al. 1976), Slow diffusion of TRH out of 
the cerebrospinal fluid into the portal system blood may maintain 
the basal level of TSH release from the pituitary gland, TRH 
release from the hypothalamus appears to be under the control of 
monoamines. Noradrenaline and dopamine have been found to
stimulate the release of TRH from mouse hypothalami in-v.ltro 
while serotonin inhibited the release, cholinergic agonists 
and antagonists having no effect (Grimm and Reichlin, 1973)• 
Edwardson et al (I98O) found no effects of prolactin nor 
growth hormone on TRH release suggesting that TRH secretion is 
controlled at a higher level than "short loop" feedback,
1 ,2.3 Hypophysiotropic Function
TRH stimulates the release of Thyroid-Stimulating Hormone 
(TSH, Thyrotropin), prolactin and, to a small extent, growth 
hormone from the adenohypophysis (anterior lobe of the pituitary). 
The TRH-stimulated release of these pituitary hormones is 
inhibited by Growth Hormone Release Inhibiting Factor (GHRIF, 
Somatostatin), Jackson and Reichlin, 1974; Reichlin et al, 1976; 
Vale et al 1977; Morley, 1979).
Schally et al (1968) reviewed the early work done on TRH extracted 
from bovine or porcine hypothalamus. TRH from either source 
increased plasma TSH concentrations in rats in-vivo and stimulated 
TSH release from rat pituitaries in-vitro. Stimulation by porcine 
TRH of TSH release from rat anterior pituitaries in-vitro was 
found to be dose dependent (0.03 - 1,08 ng TRH),
In mice in-vivo and in mouse pituitaries in-vitro, the release of 
TSH in response to TRH was inhibited by the thyroid hormones 
L-thyroxine and T^ (tri-iodothyronine), Inhibitors of protein 
synthesis, e,g, puromycin, or of transcription, e,g, actinomycin D, 
prevent this thyroid hormone effect. This suggests that L-thyroxine 
and T^ do not interact directly with TRH but rather on protein or 
RNA synthesis, perhaps leading to the production of a TSH-release- 
inhibiting factor.
Fleischer etal (l970) reported a dose-dependent increase in
plasma TSH concentrations when TRH (250 - 750 ng) was injected
intravenously (i.v.) into normal human subjects. In subjects
with pituitary disease (hypopituitarism) and in subjects
receiving L-thyroxine treatment for goitre there was little or
no increase in plasma TSH concentrations following TRH treatment
(500 - 750 ng, i,v,). It was suggested that TRH treatment could
be used as a diagnostic test for pituitary dysfunction.
Gautvik etal (198O) reported that TRH-stimulated prolactin
release from pituitary Gt^ tumour cells in culture was dependent
2+on the presence of extracellular Ga ions.
Tan and Tashjian (198I) studied the effects of TRH on ^^Ga^
fluxes in prolactin secreting GHj^ G^  pituitary cells in culture
2+and proposed that the peptide caused an initial release of Ga
from sites of adsorption on the external surface of the plasma
membrane, Goncomitant with this was a TRH-activation of specific
2+
calcium channels, causing an influx of Ga ions which was, by 
some presently unknown mechanism, transduced into the secretion of 
prolactin, .
In a small proportion of normal humans, TRH appears to produce a 
slight elevation in growth hormone secretion (Fleischer etal, 1970). 
In a variety of disease states in man, including acromegaly, 
diabetes mellitus and chronic liver disease, administration of TRH 
causes a reduction in growth hormone secretion and may be used as 
a diagnostic test to detect early abnormalities in growth hormone 
control which may lead to the onset of these conditions, (Scanlon 
and Hall, I98I),
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1.2.4 Degradation
The clearance of TRH from rat plasma and train appears to he 
first order with respect to tissue concentration (Reichlin etal 
1976) and THH-d.egrading enzymes have been identified in hypothalamic 
and extrahypothalamic tissues (Prasad and Peterkofsky, 1976).
The initial steps in the degradation of TRH appear to be deamidation 
of the G-terminal prolineamide moiety by "TRH deamidase" and 
hydrolysis of the pyroglutamate N-terminal by pyroglutamyl 
aminopeptidase (Prasad etal, 1977; Busby etal I982).
TRH deamidase has been classified as a 'post-proline cleaving 
enzyme' (Knisatschek and Bauer, 1979) or a prolyl endopeptidase,
E.G.3.4 .22.16. (Busby etal 1982) by virtue of its catalysing the 
hydrolysis of the proline amide residue. This enzyme is inhibited 
by peptides and peptide amides containing proline, e,g. Substance P 
and Angiotensin II, in a specific manner and by the antibiotic 
bacitracin nonspecifically. Deamidase activity has an optimum 
pH of about 7 .4 and, on tissue fractionation, appears to be 
cytoplasmic in distribution (Griffiths etal 1980).
The pyroglutamyl peptidase involved in TRH degradation in porcine 
serum has been characterised and in contrast to other known 
pyroglutamyl peptidases, hydrolyses the pyroglutamy1-histidine 
bond of TRH but does not hydrolyse pyroglutamyl p-naphthylamide, 
which is a substrate for the other enzymes. Moreover, the TRH 
degrading enzyme was inhibited by EDTA and dithiothreitol whereas 
the other enzymes were activated by these agents. (Bauer and 
Nowak, 1979). These findings suggest that a specific enzyme for 
TRH degradation is present in porcine serum. Griffiths et al (198O)
1 9
found peptidase activity in the particulate fraction of 
centrifuged tissue homogenates whereas Busby etal (1982) found 
activity entirely in the soluble fraction. Both groups found 
that the enzyme had a pH optimum of 8-8.4.
The metabolites of the amidase and peptidase reactions may 
undergo further catabolism as shown in Figure 3 , Matsui et al 
(1978) isolated and characterised an imidopeptidase for the 
hydrolysis of histidylprolineamide and suggested that inhibition 
of this enzyme and TRH deamidase by TSH and other peptide 
hormones, e.g. AGTH, directed TRH metabolism towards the production 
of histidylproline diketopiperazine (cyclo-His-Pro), which has 
been suggested to be an active form of TRH. (Prasad et al 1977)•
No enzyme catalysing the production of cyclo-His-Pro has yet been 
identified. This step may in fact be non-enzymic since the 
histidine amino group is sterically favoured for nucleophilic 
attack on the proline carbonyl group. Cyclo-His-Pro appears to 
undergo no further catabolism.
Figure 3 : Desradative pathways of TRH
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1,3 Extrahypothalamic TRH
1 .3 .1  Distribution
Although the highest concentration of TRH is found in the 
hypothalamus, substantial amounts, albeit at lower concentrations, 
are present in extrahypothalamic and extraneural mammalian tissues. 
Table 3 shows the distribution of TRH in the rat. (Brownstein 
et al. 1974; Jackson and Reichlin, 1974; Winokur and Utiger,
1974; Oliver et al, 1974; Morley, 1979; Burgen et al 1980).
The peptide has even been identified in invertebrates such as 
snails, which do not possess a pituitary gland, suggesting that 
the hypophysiotropic function of TRH may be a relatively recent 
use to which it has been put. (Maddrell and Nordmann, 1979).
About 70^ of the total TRH content of rat brain is present in 
extrahypothalamic tissues (Jackson and Reichlin, 1974). The 
concentration of extrahypothalamic TRH appears to be unaffected 
by lesions of the hypothalamus, suggesting that it is synthesised 
in-situ, (jackson and Reichlin 1977).
The concentrations of TRH in hypothalamic and extrahypothalamic 
loci are not fixed but exhibit circadian variations, being lowest 
during the period of darkness. Other peptides, e.g. substance P 
and LH-RH, also undergo circadian concentration changes but these 
peptides are at their highest concentrations during the period of 
darkness (Kerdelhue, I98I). The reasons for the circadian 
variation in the levels of TRH and the other peptides are not 
known,
There has been some controversy as to whether immunoreactive TRH 
found in extrahypothalamic mammalian tissues is identical with the 
tripeptide isolated from the hypothalamus.
1 4
Table 3 Distribution of iminunoreative TRH in hypothalamlc and 
extrahypothalamic tissues of the rat
Tissue TRH concentration 
(pg/mg tissue - S.E,) n = 10
Hypothalamus
Thalamus
Brain Stem
Cerebrum
Cerebellum
Anterior Pituitary
Posterior Pituitary
Liver
Kidney
Pancreas
Duodenum
Colon
Plasma
255 -  20 
^ 3 - 3
12 - 0.53
4.7 t 0.17
1.2 - 0.06
2.2 t 0.45 
70 - 16.4
0.06 - 0.01 
0.09 - 0.01
3.4 * )
1.6 * j S.E. not given 
2.1 *
0.09 - 0.01
Values from Oliver (1974) except * from Morley (1979).
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Youngblood et al (19?8, 1979) compared the chromatographic 
properties, on TLG and GLG, of TRH-like immunoreactive substances 
from rat pancreas, eye and extra-hypothalamic brain, bovine and 
sheep pineals and human serum, urine and placenta with the 
properties of synthetic TRH and TRH extracted from frog skin.
These workers found that very little of the purified extract from 
the tissues studied, which in all cases was rich in TRH-like 
immunoreactivity, co-chromatographed with authentic TRH. These 
findings cast serious doubt on whether TRH should be assigned any 
extrahypothalamic function at all. Other workers, however, tried 
to repeat the studies of Youngblood et al and found immunoreactive 
TRH to be chromatographically identical with synthetic pyroglu- 
his-pro-NHg. Kreider et al (1979) used gel filtration and TLG 
to assess the authenticity of immunoreactive TRH from rat 
hypothalamus, frontal cortex, extrahypothalamic and whole brain. 
Spindel and Wurtman (1980) used TLG and reverse phase, ion pair 
HPLG on extracts of rat brain, spinal cord and pancreas. Both 
the latter groups suggested that the results obtained ty 
Youngblood et al were artifacts of the multiple extraction 
procedures used to purify the TRH before chromatography and RIA.
The latter findings suggest that, in rat at least, immunoreactive 
TRH found in extrahypothalamic tissues is authentic TRH.
1 .3 .2  TRH binding studies
One of the conditions which must be fulfilled by a chemical found 
in nervous tissue before it may be classified as a neurotransmitter 
is the presence of specific binding sites for it in the tissue,
Burt and Snyder (1975) found both low and high affinity TRH binding 
in rat brain membrane preparations, the high affinity component 
( Kd — 50nM ) resembling that found in pituitary membranes and 
the low affinity component (Kd - 5|jM) being similar to binding in 
liver membranes.
1?
Burt (1979) further localised the regions of high affinity TRH 
binding in rat brain, finding the highest concentration of 
binding sites localised in the nucleus accumbens and septum,
Burt and Taylor (198O), and Taylor and Burt (l98l) found that 
high affinity TRH binding sites in sheep brain resembled those 
in sheep pituitary (Kj —  40 nM) and that these sites were at
the highest concentration in nucleus accumbens and septum.
In a recent paper, Taylor and Burt (1982) surveyed the regional 
distribution of binding of p H  (3-methylhistidyl) TRH to 
"TRH receptors" in the brains of rat, guinea-pig, rabbit, cat, 
dog, sheep, cattle and pig. In the rat, guinea-pig, cat and dog 
the concentrations of binding sites in the anterior pituitary were:
24.8 - 4.6, 21,4 - 5.2, 3.3 ~ 0.6 and 2.8 - 1.0 f mol/mg protein; 
those of the nucleus accumbens were: 11.3 - 1.1, I6 .8 - 5.5,
7 .2 - 0.6 and 8.6 - 4.6 f mol/mg protein; those of the dorsolateral 
septum were: 9.1 - 0.6, 8,2 - 0.7, 8,6 - 2.0 and 7 .6 - 0,8 f mol/
4“
mg protein; and those of the deep amygdala were 27.1 - 3.2,
54.0 - 8 .9, 11.1 - 1 .7 and 18.0 - 3 .4 f mol/mg protein respectively. 
In these four species the concentration of binding sites in the 
deep amygdala exceeds that in the nucleus accumbens and septum and, 
except for the rat, also exceeds that of the anterior pituitary.
The highest anterior pituitary binding was found in sheep 
(62 .4 - 9 .1 f mol/mg protein) and the highest binding in nucleus 
accumbens and septum were found in rabbit (34.9 9*7 and
,j. *
26 .2 - 4,0 f mol/mg protein respectively).
The results of this comprehensive study suggest that the effects of 
TRH which appear to originate in the nucleus accumbens and septum 
might be more fruitfully studied in the rabbit than in the rat. The 
discovery of a hitherto unsuspected TRH-sensitive region of mammalian 
brain opens another avenue of research and further complicates the 
neuropharmacology of the peptide.
_LO
1 ,3 .3  Behavioural Effects
The behavioural effects of TRH on experimental animals fall into 
two broad categories; the stimulation of locomotor activity and 
the antagonism of narcosis. These effects are thought to have 
distinct aetiologies and will be dealt with separately,
1,3.3a) Locomotor Stimulation
The DOPA potentiation test is an in-vivo pharmacological screening 
test involving the administration of L-3,4-dihydroxyphenylalanine 
(L-DOPA) and a monoamine oxidase inhibitor (MAGI) to an experimental 
animal, followed by the drug being screened, L-DOPA-plus-MAOI 
leads to elevated motor activity in mice, probably as a consequence 
of increased catecholamine concentrations in central aminergic 
synapses. TEH was found to enhance this effect (Plotnikoff et al 
1972). TRH-enhanced locomotor stimulation was found in both intact 
and hypophysectomised animals following oral or intraperitoneal 
administration of the peptide (O.l mg/kg body weight). The effects 
of TRH were found to be dose dependent up to 0.8 mg TRH/kg body 
weight and were found when TRH was given up to eight hours after 
L-DOPA-plus-MAOI. Similar results were obtained using hypophysec­
tomised animals, showing that these effects were unrelated to 
endocrine function.
Cohn et al (1975) found that TRH (50 -pg/animal), when injected
intracerebroventricularly into rats, produced tight head-to-tail
circling motions when the animals were pre-treated,by unilateral 
injections into the right striatum, with the
dopamine agonist apomorphine or with reserpine, which depletes 
vesicular stores of dopamine, Apomorphine pre-treated rats rotated 
clockwise while reserpine pre-treated rats rotated anti-clockwise, 
for a period of 30 minutes. These effects were found to be 
identical to those observed in similarly-pretreated rats given 
(+)-amphetamine (15O |ig/rat) .
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Manberg et al (1979) found the behavioural effects of TRH to be 
similar to those of (+)-amphetamine in some respects but not in 
others, for example, both drugs induced hyperthermia in rats but 
only (+)-amphetamine produced stereotyped behaviour.
1.3.3al Biochemical Basis of Locomotor Stimulation
The results obtained from behavioural studies suggest the 
involvement of catecholamines in the effects of TRH on locomotor 
activity in experimental animals. The nature of the interaction 
of TRH with catecholaminergic neurones has been studied in a number 
of laboratories.
Keller et al (1974) found that TRH (lO mg/kg body weight) increased 
the content of the noradrenaline metabolite 3-methoxy-4-hydroxyphenyl- 
ethyleneglycol (MOPEH) in rat cortex, hypothalamus, mesencephalon- 
plus-medulla oblongata and "rest of brain" in both intact and 
thyroldectomised animals. The thyroid hormone tri-iodothyronine 
(Ty) (20 jig/kg body weight) produced a less pronounced increase in 
MOPEG in intact rats in all brain regions except "rest of brain", 
where the effect was comparable with that of TRH, Since TRH did not 
induce hypothermia, which would increase noradrenaline turnover, 
nor inhibit the clearance of other amine metabolites, it was 
suggested that the increase in MOPEG produced by the peptide was 
due to increased noradrenaline release and subsequent metabolism.
Horst and Spirt (1974) found that TRH (lO mg/kg body weight, 
intraperitoneally (i.p.)) stimulated the release and turnover of 
dopamine in rat striatum and of noradrenaline in rat hypothalamus 
but not in brain stem. Chronic TRH administration over four days 
was not found to diminish catecholamine content, suggesting that 
biosynthesis was also stimulated.
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In.contrast with the foregoing findings, Reigle et al (1974) 
found no effect of acute or chronic administration of TRH on the 
metabolism of noradrenaline, serotonin nor dopamine in rat brain.
In this study, however, no separation was made between MOPEG and 
3-methoxy-4-hydroxymandelic acid (VMA) so changes in MOPEG content 
may not have been detected.
Mora et al (1979) found that conditioned behaviour in rats was 
strengthened by TRH and that this effect was antagonised by the 
tyrosine hydroxylase inhibitor oc-methyltyrosine and by the 
dopamine p-hydroxylase inhibitor disulfiram. The conditioning 
was restored by L-DOPA.
Rips et al (1979) found that dopaminergic agonists amphetamine 
(2 mg/kg i.p.), L-DOPA (200 mg/kg i.p.) and p-chloroamphetamine 
(5 mg/kg i.p.) produced hypothermia in mice when given alone and 
potentiated significantly the hyperthermia produced by TRH 
(40 mg/kg i.p.). All of these drugs have agonistic effects on 
noradrenergic as well as dopaminergic pathways. The dopamine 
receptor agonist apomorphine (l mg/kg i.p.) given alone produced 
hypothermia. When TRH and apomorphine were given together the 
effect was hyperthermia similar to that produced by TRH alone.
The antagonists haloperidol (0.5 mg/kg i.p.), pimozide (4 mg/kg i.p.), 
chlorpromazine (2 mg/kg i.p.) andoc-methyltyrosine (128 mg/kg i.p.) 
reduced but did not abolish TRH-induced hyperthermia whereas all of 
these drugs reversed the hyperthermia produced by amphetamine 
(8 mg/kg i.p.). Amphetamine-plus-TRH-induced hyperthermia was 
resistant to these antagonists.
The hypothermic effects of reserpine (l.5 mg/kg i.p.) were reversed 
15 minutes after TRH administration and 30 minutes after amphetamine 
administration. The hyperthermia produced by TRH-plus-amphetamine 
was greater in reserpine treated rats than in non-treated rats.
The results of these biochemical and pharmacological studies on 
TRH suggest that the amphetamine-like stimulatory actions of the 
peptide may be mediated through dopaminergic and/or noradrenergic 
systems.
I,3.3a2 Possible sites of action of TRH in locomotor stimulation
Two catecholamine-rich regions of rat brain have been studied in 
relation to the biochemical effects of TRH. These regions are the 
striatum and the nucleus accumbens, which are part of the nigro- 
striatal and mesolimbic dopaminergic systems, respectively.
Figure 4 shows the major dopaminergic tracts of the rat brain. 
(Cooper etal, 1976).
Miyamoto and Nagawa (1979) and Miyamoto etal (1978)showed that the 
mesolimbic system, particularly the nucleus accumbens, was sensitive 
to TRH. 5 mg TRH/kg body weight i.p. or 10 |ig TRH injected 
bilaterally into the nucleus accumbens produced strong locomotor 
stimulation. Bilateral injection of 10 jig TRH into the caudate 
nucleus of the striatal system had no effect.
Heal and Green (l979) found that TRH-induced increases in locomotor 
activity in rats were abolished by bilateral injection of 
6-hydroiîydopamine ( 8jig) into the nucleus accumbens. 
6-hydroxydopamine destroys catecholaminergic neurones, 
Intraperitoneal injection of the MAOI tranylcypromine (5 mg/kg 
body weight), followed by dopamine (5 jig) injected bilaterally 
into the nucleus accumbens produced an increased locomotor response 
in 6-hydroxydopamine treated rats.
Injection of TRH (20 mg/kg i.p.) into rats with unilateral lesions 
of the striatal system did not induce circling behaviour.
Injection of TSH (20 mg/kg i.p.) did not produce any behavioural 
changes.
Figure 4 : Ma.jor dopaminergic tracts of rat brain
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These findings suggest that TRH exerts its influence on locomotor 
activity hy causing or modulating the release of dopamine in the 
nucleus accumbens but not in the striatum and that there is no 
endocrine component to these effects.
In contrast, Gostall et al (1979) did not observe any locomotor 
stimulation following bilateral injection of TRH (20 jig) into the 
mesolimbic system, striatum, midbrain, cortex nor lateral ventricles. 
Direct injection of TRH into the nucleus accumbens failed to 
enhance amphetamine-induced locomotor stimulation or reduce the 
depression produced by the dopamine receptor antagonist haloperidol. 
Moreover, TRH'was . found to induce stereotypic behaviour in rats, at 
variance with work outlined above. The discrepancy between reports 
on work using very similar techniq^ues is difficult to reconcile 
and illustrates the uncertainties involved in in-vivo studies.
In-vitro studies have consistently implicated the nucleus accumbens 
as a site of action of TRH.
The work of Burt (1978), Burt and Snyder (1975)i Burt and Taylor
(1980) and Taylor and Burt (1981, 1982) has shown the presence of 
high-affinity TRH-binding sites in the nucleus accumbens. The 
highest concentration of binding sites for TRH in the rat, however, 
appears to be in the deep amygdala region although this region does 
not seem particularly sensitive to TRH in behavioural studies.
(Taylor and Burt, 1982).
The presence of binding sites alone does not necessarily define the 
presence of receptors unless binding is accompanied ty a physiological 
response, Kerwin and Pycock (1979) showed that TRH (25-100 jjM) 
stimulated the release of dopamine from the nucleus accumbens but 
not from the striatum. TRH did not affect the uptake of [^ h]-
dopamine into tissue slices of nucleus accumbens and neither 
basal nor dopamine-stimulated adenylate cyclase activity was 
affected. The binding of P hJ -spiperone, which binds to 
dopamine receptors, in membrane preparations of nucleus 
accumbens was also unaffected by TRH. TRH would therefore 
seem to affect primarily the release process.
Sharp et al (1981) found that TRH (lO"^) stimulated the release 
of endogenous noradrenaline and dopamine from tissue slices of 
rat nucleus accumbens and septum.
1*3.3b Antagonism of narcosis
Breese et al (1974) found that intraperitoneal injection of TRH 
into mice prior to injection of ethanol reduced the duration of 
ethanol-induced sleep but there appeared to be no clear dose- 
dependence to the effect. Sleeping time was not affected by acid- 
TRH, its constituent amino acids, amphetamine, TSH nor thyroid 
hormones. This suggests that the effect is specific to TRH and 
involves brain mechanisms separate from those involved in the 
DOPA-potentiating effects of the hormone. TRH was later shown to 
antagonise not only ethanol-induced narcosis and hypothermia but 
also the depressive effects of pentobarbital and other centrally 
acting drugs (Breese et al 1975» Gott et al 1976).
Injections of TRH into the hippocampus of hibernating ground 
squirrels have been found to wake the animals and elevate their 
body temperature even when administered during the period of 
deepest sleep (Stanton et al I98O). This effect was accompanied 
by a short latent period. Shortening of latency was dose dependent 
(0,1 - 1000 ng peptide) and was not mimicked by acid-TRH,
Early studies (Prange et al, 1972; Prange and Wilson, 1972;
Kastin et al, 1972) on depressed human subjects suggested that TRH 
had an antidepressant effect but later workers did not confirm this 
hypothesis (Dimitrihoudi et al, 1974; Morley, 1979).
1.3.3bl Biochemical Basis of Antagonism of Narcosis
Breese etal (l975) and Gott etal (1976) found that TRH antagonism 
of ethanol and barbiturate narcosis was reduced and in some cases 
abolished by the muscarinic receptor antagonist atropine. This 
suggests that the peptide exerts its antinarcotic effects via 
cholinergic neurones. It was, however, found that the cholinergic 
agonist carbachol also reduced ethanol sleeping time in mice but 
appeared to antagonise TRH so that both drugs given together had
i£U
no effect on sleeping time. This suggests that TRH may not 
interact directly with cholinergic neurones,
Gott et al (1976) found that there was no significant difference 
between the concentration of ethanol in the brains of TRH-treated
and untreated rats. This suggests that the antagonism of ethanol
narcosis by TRH cannot be attributed to an increase in ethanol
metabolism in the treated animals.
Malthe-S^ronssen et al (1978) found that intraventricular injection 
of TRH, somatostatin, neurotensin and angiotensin II all decreased 
the acetylcholine (AGh) content of rat brain parietal cortex but 
not that of the frontal cortex. TRH increased AGh turnover in 
parietal cortex but had no effect on hippocampus, pons-medulla nor 
diencephalon. None of the synthetic peptides L-prolylglycine, 
poly-L-proline and poly-L-glutamate had any effect on AGh turnover 
in any brain region tested, suggestingthat TRH had specific actions.
1.3«3b2 Possible sites of action of TRH antagonism of narcosis
Kalivas and Horita (198O) using antagonism of pentobarbital narcosis 
as the parameter, identified TRH-sensitive areas in the rat brain by 
injecting picomolar concentrations of the peptide through 
stereotaxically implanted cannulae. On this basis, TRH-sensitive 
sites seemed to be clustered in the lateral and medial septum, while 
the mesolimbic and striatal areas were found to be insensitive.
It has more recently been found that the antagonism of pentobarbital 
narcosis by TRH is blocked by lesions in the septum and fimbria of 
the septohippocampai system but not by lesions of the dorsal 
hippocampus (Kalivas, Simasko and Horita, 1981). Electrolytic 
lesioning of the septum blocked TRH-antagonism of narcosis, but 
lesioning by kainic acid, which destroys cell bodies, did not. This 
suggests that nerve fibres passing through the septum and fimbria, 
originating and terminating in presently unknown locations are 
involved in these TRH effects.
There is some evidence to suggest that the effects of TRH on body 
temperature may be peripheral in origin, Boschi and Rips (198I) 
found that intraperitoneal (i.p.) injections of TRH (40 mg TRH/kg 
body weight) into mice reversed the hypothermia induced ly 
intracerebroventricular (i.c.v.) injection of noradrenaline 
(NA, 20 jig/mouse). The same dose of TRH (i.p.) was found to produce 
hyperthermia which was increased by i.p. NA (l mg NA/kg body weight), 
I.c.v. injections of TRH did not produce hyperthermia. This suggests 
that noradrenergic systems, perhaps including peripheral ones, may 
be involved in the hyperthermia and reversal of hypothermia caused 
by TRH.
1,3.4 Interaction between TRH and neurotransmitters other than 
catecholamines and acetylcholine
Biochemical and pharmacological studies on TRH and its analogues 
have indicated that the peptide may interact with putative 
neurotransmitters other than catecholamines and acetylcholine to 
exert its behavioural effects,
Bennett and Edward son (l97?) observed that TRH enhanced K**-induced 
release of glycine and, to a lesser extent, glutamate, aspartate 
and )^-aminobutyrate (GABA) from synaptosones of sheep brain-stem 
and rat cortex. Basal release of amino acids was unaffected.
Neither somatostatin nor LH-RH mimicked these effects, suggesting 
that TRH had a specific neuromodulatory effect.
Gott and Engel (1977) found that the GABA agonists 5f-hydroxybutyric 
acid (GHBA), baclophen and aminooxyacetic acid (AOAA) inhibited TRH 
effects on ethanol narcosis and locomotor stimulation in mice.
These reaiilts suggest that the behavioural effects of TRH may be 
mediated through an inhibition of GABA systems. Bjbrkman et al
(1981) found that the effects of TRH on mice treated with reserpine, 
tremor and reversal of hypothermia, was inhibited by GHBA and 
baclophen but not by the more specific GABA agonists ^-acetylenic 
GABA and sodium valproate, GHBA and baclophen, while producing 
effects similar to GABAergic stimulation, do not act on 
bicuculine-sensitive GABA receptors and are therefore thought not 
to be specific GABA agonists. Moreover, the GABA antagonist picrotoxin 
neither potentiated nor inhibited the TRH effects. These findings 
refute the hypothesis that TRH exerts its behavioural effects via 
GABAergic systems.
The same workers also found that the effects of TRH on reserpine- 
treated mice were unaffected by antagonists of cholinergic, 
serotonergic, adrenergic, dopaminergic and histaminergic receptors, 
which leaves the true origin of these effects uncertain.
The TRH analogue pyro-2-aminoadipyl-histidyl-thiazolidine-4- 
carboxamide (mK-7?1; see Figure 5» page 37 ) is almost equipotent
with TRH in its hypophysiotropic effects but is of the order of 
10-times as potent in eliciting a wide range of TRH-like 
behavioural effects, including antagonism of ethanol, pentobarbital 
and chlorpromazine narcoses and enhancement of motor activity in 
mice. (Yarbrough, 1979).
Rastogi et al (198I) studied the effects of MK-771 on rat brain 
dopaminergic and serotonergic systems. It was found that 
15 mg MK-771/kg body weight increased dopamine synthesis in 
striatum, hypothalamus and pons-medulla and dopamine turnover 
in striatum and olfactory tubercle. 5-HT synthesis and turnover 
were increased by the same peptide concentration in hippocampus, 
hypothalamus, mid-brain and pons-medulla. Mid-brain tyrosine 
hydroxylase and tryptophan hydroxylase activities were enhanced.
The increased potency of this synthetic peptide in the GNS may 
reveal effects of TRH too small to be observed with the natural 
peptide,
1,3.5 Interaction of TRH with other neuroactive peptides
In addition to those effects of TRH which appear to act directly on
some aspect of neural function, the peptide also appears to interact
with other neuroactive peptides, modifying their effects on nervous 
tissue. Observations of such interactions give;.an insight into 
possible fine-control mechanisms of the central nervous system.
The endogenous tridecapeptide neurotensin (NT) produces a hypothermic 
response in rats, potentiates neuroleptic and ethanol sleeping time 
and hypothermia, causes muscle relaxation, analgesia and decreases 
the active avoidance response in the "shuttle-box" behavioural 
paradigm. All of the above effects are antagonised by TRH 
(Nemeroff et al, 1980; Burgess et al, I98I),
The hypothermic response to NT is blocked by pretreatment of the 
animals with 6-hydroxydopamine, which depletes brain catecholamines, 
but is not blocked by antagonists of cholinergic, opiate, serotonergic 
nor noradrenergic systems. The ineffectiveness of noradrenergic 
antagonists suggests the involvement of dopaminergic neurones, 
NT-induced hypothermia is augmented by the dopamine receptor 
antagonist haloperidol and by selective depletions of brain dopamine 
using desmethyllmlpramine (Nemeroff et al 1980), The basic mechanism(s) 
underlying the antagonistic effects of TRH on NT are presently 
unknown but may involve dopaminergic neurones.
The opiate p-endorphin produced a number of behavioural effects in 
rats, including reduction in motor activity, hypothermia, increased 
salivation and antinocic.eptloru . TRH inhibits all of these effects 
except antinociception whereas all of the effects of p-endorphin are 
inhibited by the opiate receptor antagonist naloxone. This suggests 
that the TRH effects are not mediated directly via opiate receptors 
(Tache et al. 1977» Holaday et al, 1978).
-endorphin inhibits the release of noradrenaline from rat cerebral 
cortex (Arbilla and Langer, 1977) and of dopamine from rat striatal 
slices (Xoh“'.\ et al 1976) . Since TRH is reported to affect the 
turnover and release of catecholamines (see Section 3.3)» TRH may 
cause inhibition of opiate systems indirectly, by its effects on 
dopaminergic or noradrenergic neurones.
p-endorphin stimulates the release of prolactin and growth hormone 
from rat pituitary in vivo.TRH has a mixed effect on this response, 
elevating prolactin levels and reducing growth hormone levels in the 
plasma of p-endorphin-treated rats. (Taché et al 1977). The 
opiate is inactive as a releasing factor in mouse pituitary incubates 
in-vitro, suggesting that its actions.may be of central nervous system 
origin.
1,3.6 Effects of TRH on neuronal activity
Glucose utilisation may be used as a measure of neuronal activity 
and can be followed by giving rats injections of -
2-deoxyglucose, which is taken up into cells by the glucose 
"carrier" but is not metabolised. The tissue being studied may 
then be sectioned and autoradiographed to visualise regions of 
active glucose utilisation. Hagai et al (l980) used this method 
to study the effects of TRH on glucose uptake in the brains of 
conscious and pentobarbital-anaesthetised rats. In conscious rats, 
glucose utilisation was found to be widespread and very active.
TRH alone caused a generalised mild depression of utilisation. 
Pentobarbital caused severe widespread depression, which was 
antagonised by TRH in numerous loci, the most sensitive areas 
appearing to be the septum and the nucleus accumbens. This finding 
presumably reflects the sensitivities of these areas for TRH without 
necessarily proving that they are both involved in the behavioural 
effects of the peptide in anaesthetised animals, 
lontophoretic studies on the effects of TRH on neuronal activity 
have shown both excitatory and inhibitory effects, TRH has been 
shown to inhibit spontaneous or glutamate-evoked electrical activity 
in neurones of rat cerebellar and cerebral cortex, ventromedial 
hypothalamus (Renaud and Martin, 1974; Renaud, Martin and Brazeau, 
1974) and rostral hypothalamus (l)yer and By ball 1974) .
Yarbrough (1976) found TRH to potentiate the excitatory effects of 
acetylcholine on rat cerebral cortex neurones.
1.3.7 THH and cyclic nucleotides
The influence of TRH on intracellular levels of cyclic AMP 
(adenosine 3'»5’”monophosphate) and cyclic GMP (guanosine 
3’,5'-monophosphate) in mammalian hrain varies between brain 
regions studied.
Gautvik et al (1980) discovered that TRH elevated levels of cyclic 
AMP in cultured rat GH3 pituitary tumour cells,
Tsang and Martin (1976) and Tsang et al (l980) found that TRH 
depressed noradrenaline-induced increases in cyclic AMP in rat and 
human pineal glands but did not affect basal cyclic AMP levels,
TRH was effective in this respect at 0.1 pg/ml whereas LH-RH, 
somatostatin and "DDD-TRH" (d-pyro-glutamyl-d-histidyl-d-prolineamide, 
the enantiomer of natural TRH) were required at much higher 
concentrations to reduce significantly noradrenaline-induced increases 
in cyclic AMP levels in this tissue.
Mailman et al (1978, 1979) found that TRH increased basal levels of 
cyclic GMP in the cerebellum of normal rats and rats treated with a 
range of anaesthetics, including ethanol and phénobarbital. No change 
in cyclic AMP levels were observed. The receptor antagonists atropine, 
atropine methylnitrate, chlorpromazine and morphine had no effect on 
TRH-induced increases in cyclic GMP, indicating that this effect, in 
cerebellum at least, was not related to activation of cholinergic, 
dopaminergic nor opiate receptors. Acid-TRH had no effect on cyclic 
GMP levels, suggesting that a specific TRH effect was being observed. 
Green et al (1976) found that neither TRH nor the protein synthesis 
inhibitor cycloheximide affected dopamine-sensitive adenylate cyclase 
activity in rat caudate nucleus.
1.3.8 Effects of TRH metabolites
The metabolic products of TRH degradation which have been used in 
behavioural and biochemical studies are deamido-TRH (acid-TRH) 
and histidylproline diketopiperazine (cyclo-His-Pro). See Figure 3.
These compounds are the major products of TRH degradation in rat 
serum and brain tissue homogenates and have been studied to determine 
whether they represent "active formd’ of TRH.
Acid-TRH has been found to be inactive as a hypophysiotropic factor, 
(Reichlin et al 1976). It also lacks any effect on cyclic nucleotide 
levels (Mailman et al 1978, 1979) and does not antagonise ethanol 
narcosis (Prasad et al 1977) under conditions where TRH is active in 
these respects. Therefore acid-TRH appears to be a deactivated form 
of the parent peptide,
Prasad et al (l977) found that histidylproline diketopiperazine, when 
injected intraventricularly into rats at a dose of 1 jimol peptide/ 
kg body weight reduced ethanol sleeping time to 50^ that of the control 
duration, whereas 70 ji mol TRH/kg body weight was required to produce 
the same effect. However, in the same study, the dipeptide did not 
mimic TRH-antagonism of pentobarbital narcosis,
Bhargava (198O) found that both TRH and cyclo-His-Pro antagonised the 
hypothermia induced by delta-9-tetrahydrocannabinol when injected 
intracerebrally into mice at doses of 1 or 10 jog peptide/mouse.
Only TRH had this effect when the route of administration was 
intraperitoneal injection,
Griffiths et al (198I) found that cyclo-His-Pro completely antagonised 
TRH-induced locomotor stimulation but did not antagonise 
d-amphetamine-induced hyperactivity. The dipeptide alone caused some 
stereotyped movements when injected directly into the nucleus accumbens.
Reports of cyclo-Hls-Pro effects on release of prolactin vary,
Bauer et al (1978) found that cyclo-Hls-Pro inhibited both basal 
and TRH-stimulated release of prolactin from pituitary GH3 tumour 
cells. Lamberts and Visser (198I) found that cyclo-His-Pro only 
weakly inhibited basal prolactin release from normal cultured 
pituitary cells and had no effect on TRH stimulation nor on dopamine 
inhibition of prolactin release in the same system.
The findings of these studies suggest that conversion to cyclo-His-Pro 
may produce or modulate some of the effects of TRH observed in rats 
but do not suggest that cyclo-His-Pro is the universally active form 
of TRH.
1.3.9 TRH analogues
A number of structural analogues to TRH are commercially available 
and some of these are shown in Figure 5. These synthetic peptides 
have been found to be potent in mimicking the effects of TRH in 
neuropharmacological tests and behavioural paradigms (Flohe et al 1981; 
Heal et al I98I).
It has been suggested that the increased potency of these analogues 
is due to their resistance to TRH-degrading enzymes and hence 
increased biological half-lives. (Brewster etal 1980, 1981; Cowan 
and Vaught I98I; Dettmar et al 198I), Griffiths et al (198I) 
identified the metabolic products of some of the TRH analogues 
incubated with rat brain subcellular fractions. The order of 
resistance appeared to be:
RX77368>  cG3509>PGHPA>GG3703<TRH, 
an order which appears to be reflected to some extent in the potencies 
of the peptides since the same workers found RX77368 and CG3509 to 
have the greatest biological activity
Flohe et al (1981) agreed with the finding that CG3509 had increased 
stability and biological activity over that of TRH but suggested that, 
from these points of view, CG3703 was the best analogue with which to 
investigate the effects of TRH in the central nervous system,
Hennies and Flohe (1982) found that GG3703 reduced the noradrenaline 
content of mouse brain in a dose-dependent manner (O,01-1.0  mg/kg 
body weight, i.p,) in mice treated with the tyrosine hydroxylase 
inhibitor ot-methyltyrosine, TRH was about 8OX less effective than 
GG3703. These findings suggest that CG3703 enhances the turnover of 
noradrenaline in mouse brain, an effect of TRH which may go unseen due 
to the natural peptide's rapid degradation in brain tissue. GG3703 
did not affect the levels, rate of biosynthesis nor rate of utilisation
Figure 5 : TRH and some of its analogues
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of serotonin in rat train. It was therefore suggested that the 
"wet dog shakes" induced in rats by TRH were due to the peptide’s 
actions on dopaminergic rather than serotonergic systems. This 
finding agrees with those of Hennies et al (198I) who found that 
"wet dog shakes" were antagonised by haloperidol, pimozide, 
chlorpromazine and propranolol more effectively than by serotonin 
receptor antagonists methy-sergide and cyproheptadine.
The analogue MK-771 appears to be equipotent with TRH in releasing 
TSH in rats but is more potent than TRH in inducing "wet dog shakes" 
in rats. (Cowan and Vaught, I98I). This analogue may be found a 
clinical use in treating narcolepsy since it has amphetamine-like 
stimulant effects but in behavioural tests on rats there appears to 
be no incentive for the animals to self-administer the drug, possibly 
indicating a reduced risk of addiction to this compound (Yarbrough,
1979).
The analogue DN-1417 has less endocrine activity than TRH but has 
been found to be more potent than TRH in depolarising the ventral 
root of rat spinal cord and in increasing the mono-synaptic reflex. 
(Ono and Fukuda, I982). This analogue did not affect the membrane 
potential of the dorsal root nor increase the dorsal root reflex.
The effects on the ventral root were not inhibited by chlorpromazine, 
haloperidol, atropine, cyproheptadine, baclophen, tetrodotoxin nor 
by pre-treatment with reserpine. These results suggest that both 
TRH and DN-1417 directly depolarise motoneurone membranes.
Fukuda et al (1980) chemically synthesised three classes of TRH 
analogues and tested them for endocrine and central nervous system 
activity. The analogues were classified by their N-terminals, 
being Y-butyrolactone-X-oarbonyl (Blc) (c.f. DN-1417),
2-ketopiperidine-6-car'bonyl (Kpc) (= pyro-2-aminoadipyl, c.f. MK-771) 
and 3“OXoperhydro-l,4-thiazine-5-carbonyl (Otc) (= 5-oxothiomorpholinyl-
3-carbonyl, cf. CG3703)» and had prolineamide G-terminals 
substituted with various aliphatic and aromatic groups.
The analogues most effective in antagonism of pentobarbital sleep 
and potentiation of apomorphine-induced circling behaviour, 
Blc-his-pro-Nïïg» Blc-3-methyl his-pro-NH^, Otc-his-pro-NH^ and 
Otc-his-pro-NH-nbutyl were tested for TSH-releasing activity. The 
Blc peptides were less active than TRH in releasing TSH from mouse 
pituitary (relative potencies w.r.t. TRH ; 0.024 and O .196 
respectively) whereas the Otc peptides were slightly more active 
than TRH (relative potencies w.r.t. TRH ; 1.58 and 1.19
respectively). It was suggested that the analogue Blc-his-pro-NH^ 
(DN-1417) should be used to model central nervous system effects 
of TRH since its GNS effects were approximately 3-6 x more potent 
than TRH and its endocrine effects approximately 40x less potent.
Concluding Remarks
The discovery and identification of a factor from the hypothalamus 
which stimulated the release of TSH from the pituitary was a step 
towards the further understanding of control of pituitary and 
endocrine functions; the discovery that the same factor could 
affect animal "behaviour and its identification in extrahypothalamic 
tissues introduced the possibility of another level of control of 
function of the central nervous system.
As work on TRH has progressed in numerous laboratories, the more 
it seems that this peptide may be performing different functions 
in different locations, ruling out the possibility of finding a 
unifyirg hypothesis for its actions. Despite these complications, 
the overall "behavioural effects of TRH appear to be those of 
activation and reversal of depressed states and the use of 
degradation resistant analogues may further elucidate the in vivo 
function(s) of the natural hormone.
It has been suggested (Morley, 1979) that, since the wide range 
of effects of TRH and its wide distribution are now more fully 
appreciated, the name Thyrotropin-Releasing Hormone may itself no 
longer be adequate for this peptide and should be changed to 
Ubiquitous Regulatory Factor (U.R.F.) or, with deference to its 
discoverers, Guillemin Schally Factor (G.S.F.),
1.5 Introduction to Research Project
This project was initiated to study the biochemical effects of 
TRH on in vitro preparations of rat brain, with respect to 
neurotransmitter biochemistry.
Earlier work in this laboratory (Shapiro, L.M., PhD thesis, 1978; 
Shapiro, Bowes and Vaughan, I98O) suggested possible effects of 
TRH on the dopamine metabolism of rat caudate nucleus. High 
concentrations of TRH (lO M) were required to produce changes in 
dopamine turnover and release,
Kerwin and Pycock (1979) showed stimulation of release of pre- 
loaded dopamine from rat nucleus accumbens "hy TRH at peptide 
concentrations of 25-100 joM, whereas the caudate nucleus was found 
to be insensitive. The former region was therefore chosen to 
study TRH-stimulation or modulation of release of dopamine from 
"tissue cube" or "synaptosome" preparations of tissue.
This line of research was followed for most of the project.
Later work studied the effects of TRH, histidylproline 
diketopiperazine and the analogue CG3703 on release of 
acetylcholine from nucleus accumbens and septum.
II MATERIALS AND METHODS
2.1 Materials
Analar reagents were used throughout
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Radiochemicals
7,8- |_^ H I -dopamine HOI 
250jiGi/250]al
îy - choline chloride 
250uCi/250ul
|l4 1L Qj -acetylcholine chloride 
50]iOi/250|il
Specific Activity 
44 Gi/m mol
60 Gi/m mol
26,5mCi/m mol
from Amersham International FLO, Amersham, Bucks., U.K.
Enzyme inhibitors
Pargyline HGl Sigma London Chemical Go,Ltd., 
Poole, Dorset, U.K.
Bacitracin
Physostigmine (eserine)
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Drugs
Tyramine HGl BDH Chemicals Ltd., 
Poole, Dorset, U.K.
TRH acetate Serva, c/o Micro-Bio Labs, 
London, U.K. or
Pierce, Pierce and Harriner Ltd., 
Cheshire, U.K. or
Sigma London Go.Ltd.
TRH analogue CG3703 Gift from Dr.L.Flohe,
Grünenthal GmbH, West Germany
Histidylproline diketopiperazine Pierce, Pierce and Harriner Ltd,
Fine Chemicals used in HPLG and TLG 
Noradrenaline HGl 
Dopamine HGl
1-heptane sulphonate
Octyl sulphonate
Partisil ODS-10
Partisil Go : Pel
Cellulose TLG plates
(without fluorescent indicator)
Choline Chloride
Acetylcholine chloride
Ghloroplatinic acid
BDH Chemicals Ltd 
BDH Chemicals Ltd
Fisons Go.Ltd.
Whatman Inc.
Ê.Merck, AG Darmstat FRG
Sigma London Ltd
Gift from Dr.Kamal Aziz, 
Department of Chemistry, 
Glasgow University
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Other Chemicals
2-amino-2-hydroj<ymethylpropane-l,3-diol
(TRIS)
Imidazole HGl 
Bovine serum albumin
Sodium pyruvate
Sigma London Ltd,
Ascorbic acid BDH Chemicals Ltd
Folin-Ciocalteau reagent
Sodium dodecyl sulphate
N-2-Hydroxyethylpiperazine-N -2- 
ethane sulphonic acid (HEPES)
Reduced nicotinamide adenine 
dinucleotide, disodium (NADH)
PL Biochemicals Inc., 
c/o International Enzymes Ltd,, 
Windsor, Berks, U.K.
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2.2 Buffered salines
The buffered saline used in the filtration assay and some of the 
perfusion assays was that of Dayton et al (1979) a-nd consisted of: 
5mM-N-2-hydroxyethylpiperazine-N' -2-ethane sulphonic acid (HEPES), 
5mM-KGl, 120mM-NaGl, ImM-Mg SO^, ImM-glucose, P.^mM-GaGlg, 0.5mM- 
ascorbic acid and 0 .ImM-pargyline.
The pH of the saline was adjusted to pH 7.4 or pH 6.5 by addition 
of concentrated HGl.
The TRlS-buffered saline used in the perfusion and centrifugation 
assays was similar to that of Phizakerley and Fixter (1973)i based 
on Krebs (l950) and consisted of:
20mM-2-amino-2-hydroxymethylpropane-l,3-diol (TRIS), 120mM-NaCl,
■ 3.5mMNaHG0^, 5mM-KGl, ImM-Mg SO^, l.PmM-KH^ PO^ ,^, 11.5mM-glucose,
0 .5mM-ascorbic acid, 0.ImM-pargyline and 2.5mM-GaGl2. The pH of
the saline was adjusted to 7.4 or 6.5 by the addition of concentrated
HGl.
When 50mM-KGl was used the Na G1 concentration was decreased to 
75 mM.
In some cases, as indicated in the Results section, the TRIS was 
replaced by 20mM-imidazole,
1-litre batches of buffered salines, without glucose or ascorbic 
acid, were stored at 4°G. Glucose and ascorbic acid were added 
before each assay in a final volume of 100 ml saline.
Solutions containing TRH and other peptides (10"^-10"^M) also 
contained 50 jig bacitracin/ml to reduce degradation of the peptide. 
Solutions used in assays for acetylcholine also contained O.lmM- 
physostigmine to inhibit acetylcholinesterase.
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2.3 Tissue preparation
2 .3 .1  Dissection
Male Wistar rats (250 - 50g) were killed ty cervical dislocation 
and decapitated. Brains were removed and placed in a petri dish on 
a filter paper (Whatman No.l, W.R.Balston Ltd., London) moistened 
with ice-cold HEPES, TRIS or imidazole buffered saline to await 
dissection.
For the dissection of nuclei accumbens, a coronal section was made 
2mm rostral to the optic chiasma and a second section at the optic 
chiasms. The slice of tissue produced was placed rostral aspect 
uppermost and the nuclei accumbens dissected by the method of Horn 
et al (1974) as shown in Figure 6.
Striata were dissected following the instructions of Glowinski and 
Iversen (1966) (Figure 7). Tissue which did not appear flecked or 
striated in colour was discarded.
For the dissection of septa a coronal section was made at the optic 
chiasma and a second section 3 mm caudal to the optic chiasma.
The slice of tissue produced was placed rostral aspect uppermost and 
the septal region dissected by the method of Marsden (Dr.G.A.Marsden, 
Department of Physiology and Pharmacology, University of Nottingham 
Medical School ; personal communication) as shown in Figure 8 . 
Hypothalami were dissected from the same section of brain as the 
striata, following the instructions of Glowinski and Iversen (1966 ; 
Figure 7).
Figure 6 ; Dissection of nucleus accumbens
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Corpus
N u e  Ieus„accumbens
A n c e r  io r^ c o m m is u re
O lfa cc o ry ._ c u b e  r d e
Rostral aspect of coronal section 2 mm rostral to optic chiasma, 
Half of brain is shown.
Figure 7 : Dissection of striatum and hypothalamus
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O p t i c  chiasma
a)saggital section of larain, showing internal and external structures 
and positions of coronal sections (AA',BB') made in intact hrain for 
the dissection of striatum and hypothalamus.
h)Rostral aspect of section 
AA'-BB'. Half of train 
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L a t e r a l  
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A n te r  lo r  
com m isure
'Hypothalamu:
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7i^ure 8 Dissection of septum
C o r t e x
C o rp us  c a l I o s u m _ __
S e p t u m ________ _
Cor.pus_stria.tum
M uc  le us,.accumbens
Rostral aspect of 3 mm-thick coronal section immediately caudal to 
optic chiasma. Half of brain is shown.
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2.3*2 Tissue cube preparation
Tissue.from striatum, nucleus accumbens or septum was placed on 
filter paper (Whatman No.l), moistened with 5mM-HEPES-,20mM-TRIS- 
or 20mM imidazole-buffered saline, pH 7.4, containing 5mM-KGl,and 
chopped in two planes at 90^ to one another using a tissue slicer 
set at 0.2mm (H.Mickle Ltd., based on the design of Mclllwain and 
Buddie, 1953)• The tissue fragments were suspended in l-4ml of 
5mM-HEPES-, 20mM-TRIS- or 20mM-imidazole buffered saline, pH 7*4, 
containing 5mM-KGl, for preloading with pH^ -dopamine, or pH^] - 
choline as outlined in the assay methods,
2 .3 .3 . P2 preparation
Crude synaptosomes (P2 fractions) were prepared from striatal or 
nucleus accumbens tissue as shown in Figure 9. based on the method 
of Gray and Whittaker (1962). No further steps were taken to 
purify the nerve-ending fraction of this P2 preparation.
The integrity of the preparation was determined by the LDH assay 
(Section 2.4.1). The preparation was characterised as containing 
nerve ending particles by electron microscopy. Electron 
micrographs of P2 preparations were prepared by Mr.I.Montgomery, 
Physiology Department, Glasgow University.
2 .3 .4  Metabolic viability of tissue cubes of nucleus accumbens before and 
after pre-loading and washing 
Tissue cubes of rat nucleus accumbens (20 - 40 mg wet weight) were 
placed in an oxygen electrode chamber (Rank Bros., Gam bridge, U.K.) 
containing 2 ml 20 mM TRIS-buffered saline, pH 7.4 with 5 mM-KGl at 
37 G, which had been allowed to equilibrate with the atmosphere.
The rate of oxygen consumption was measured on a chart recorder 
(Rickadenki, Tohsin Electron Go.) for at least 2 minutes.
Figure 9 : Crude Synaptosome (P2) Preparation
4?
D i s s e c t e d  t i ssue
Homogenise on ice 10 volumes 
0.32M sucrose, pH 7,4
H o m o g e n a t e
Centrifuge, 1000 g, 4 G, 10 minutes
Pellet PI. 
( d i s c a r d e d  )
Supernatant  SI
Centrifuge, 10,000 g 
4 G, 15 minutes
Pel l e t  P2_ S u p e r n a t a n t . S 2  
. ( d i s c a r d e d )
Wash 3x try resuspension in 5 ml 
TRIS buffered saline, pH 7.4 and 
recentrifugation at 4^G for 10 minutes 
at 10,000 g
W a s h e d  _.pelJ e t
Resuspend in 3-4 ml TRIS buffered 
saline, pH 7.4,
Y
C r u d e  
s yn ap t o so me  
i . P 2 . J . p r e p a r a t i o n
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100 n moles of KCl was then added to the suspension of tissue cubes 
and the rate of oxygen consumption measured,
A second batch of tissue cubes (20-40 mg wet weight) were placed in 
1 ml of 20 mM-TRIS buffered saline, pH 7.4, containing 5mM-KCl,/50 mg 
tissue at 37°G with shaking for 30 minutes. The tissue suspension was 
centrifuged at 10,000g for 10 minutes at 4^0 in the MSE 18 centrifuge 
and resuspended and recentrifuged three times in 20mM-TRIS buffered 
saline pH 7.4 containing 5mM KOI, The final pellet was resuspended 
in 2 ml of the same saline and rates of respiration in the presence of 
5 mM- and 50 mM - KOI determined using the oxygen electrode.
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2.4 Assays
2.4,1 Lactate dehydrogenase assay (lDH ; E.G.1,1,1,2?)
The integrity of the nerve ending particles in the crude P2 preparation 
was determined "by measuring the proportion of occluded lactate 
dehydrogenase iy the method of Johnson (1960),
Free LDH activity was measured by adding 100 |il of P2 fraction 
(0 .0 5 - 0 .07 mg protein) to a cuvette in a Beckman Dual Beam 
spectrophotometer (Beckman Ltd., High Hycombe, Bucks., U.K.), which 
contained 2,9 ml NaH^PO^Na^HPOj^ buffer, pH 7.4 (final concentration 
50 mM) containing sodium pyruvate (final concentration 0,33 mM) and 
disodium NADH (final concentration 80 jjyi) , Absorbance (A^^q) was 
measured every 15 seconds.
After a steady rate of oxidation had been reached 0.2 ml 10^ (v/v)
Triton X-100 was added to the cuvette to lyse vesicles fori measurement of 
the total LDH activity in the P2 preparation, A^ 2|0 measured 
every 10 seconds (Figure lO),
The percentage of the total activity which was occluded by the nerve
ending particles was calculated thus:
1 “ (free activity ) x 100^ (Marchb)anks, I967)
(total activity
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2.4.2 Assay of endogenous catecholamines from rat brain regions
Endogenous noradrenaline and dopamine were assayed "by reversed phase 
(ion pair) high-performance liquid chromatography with electrochemical 
detection (HPLC-EG) using the apparatus shown in Figure 11.
Rat train tissue (one hypothalamus, half-pair of striata or half­
pair of nuclei accumhens) was weighed and homogenised in 200 |il 
0,1 M - HGIO^ (containing 400 |il IM-NaHSO^/l) using a mini-drill 
(Expo Drills Ltd., London, U.K.) as an homogeniser with a teflon- 
tipped pestle, in microcentrifuge tuhes (Eppendorf GmhH, Hamburg, F.R.G,), 
The tubes were centrifuged at 10,000 g for 2 minutes at 20°G in an 
Eppendorf 5412 bench centrifuge and the volume of liquid in each tube 
made up to 400 jol. Samples were stored at -20°G prior to assay.
After thawing, aliquots of supernatant were injected onto a Partisil- 
10 CDS column (Whatman Ltd., 25 cm x 4,6 mm i.d.) via a six port 
rotary injection valve (Model 7120, Rheodyne Instruments Ltd., U.S.A.) 
fitted with a 100 |il sample loop. Separation of catecholamines was 
achieved using ion-pair, reversed phase chromatography (Knox and 
Jurand, 197&) with a mobile phase of O.IM-KH^PO^ (pH 3.5), 0.2mM— 
sodium octyl sulphonate, 0.04 mM EDTA and 5-10$^  (v /v )  methanol. The 
mobile phase was filtered through Sartorius filters (0.45 pm pore size) 
before use, degassed ty helium and delivered at a constant flow rate 
of 1 ml/min using an LG3-XP'pump (pye Unicam Ltd., Cambridge, U.K.).
At the start of the project, catecholamines were measured using a home 
made electrochemical detector cell and controller unit. The detector 
cell consisted of a carbon-paste working electrode (silicon-grease 
based carbon paste, GP-Si, Bio-Analytical Systems Inc), Ag/AgGl 
reference electrode and platinum auxiliary electrode. The operating 
potential of this system was 0.55V and the sensitivity of the controller
Figure 11 : HPLG-EG System
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Sampl e  loop
H e
Pump
M o b i  le phase  
r e s e r v o i r I n j e c t o r
assembl y
H P L C
column
A u x i l i a r y
e l e c t r o d e
W o r k i n g
e l e c t r o d e
To  ampi  i f  i e r  
p o t e n t i o s t a t  
and r e c o r d e r
R e f e r e n c e
e l e c t r o d e
DO
fixed at about 50nA/V.
Later assays for catecholamines were carried out using a TL-5 
electrochemical detector cell (consisting of a glassy-carbon working 
electrode, Ag/AgGl reference electrode and a platinum auxiliary 
electrode) and a LG-4 Gontroller Unit (Bio-Analytical Systems Inc.).
The operating potential was 0.55V and the current produced by oxid­
ation of catecholamines was transduced by the LG-4 Gontroller Unit 
into a peak on a Philips PM 8251 single pen chart recorder (Philips Ltd.) 
The retention time of noradrenaline was about 6 minutes and that of 
dopamine about 12 minutes (Figure 12). Peak heights of samples 
were compared with the peak heights produced by standard solutions 
of noradrenaline and dopamine (4-20 ng/lOO jil in O.IM - HGIO^) and 
the unknown concentrations calculated from the calibration curve for 
each catecholamine (Figure 13).■ A linear relationship between 
catecholamine content and peak height was obtained up to at least 
20 ng catecholamine.
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Figure 12 : Elution of dopamine and noradrenaline from reversed-phase
HPLG column 
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2,4.3. Release of endogenous dopamine
Six pairs of rat nuclei accumbens (about 65 mg wet weight) were 
chopped into tissue cubes and suspended in 3*5 ml of 20 mM-TRIS 
buffered saline, pH 7.4, containing 5 mM-KGl , 500 jil of this
suspension was added to 500 jil 20 mM-TRIS buffered saline, pH 7*4 
in a glass bijQU (control) and 2,500 jil of suspension was added to 500 |uL 
TRIS buffered saline with 300 mM-KGl in a duplicate glass bijou (K"^ ) .
500 ul aliquots were removed from the "K"^ " bijou after 0, 5, 10, 20 
and 30 minutes incubation at 37°G and a 500 jil aliquot was taken 
from the "control" bz^ bu at 30 minutes. Between samples the tissue 
was kept suspended by sucking up and ejecting the suspension with the 
adjustable pipette used to take the samples.
The samples were placed in microcentrifuge tubes (Eppendorf) and 
immediately centrifuged at 10,000 g for 2 minutes at 20°G in the 
Eppendorf 5412 bench centrifuge. 400 |il of the supernatant was 
transferred to another microcentrifuge tube and the remaining 
supernatant removed by aspiration.
The pellets were homogenised in 100 |il O.IM-HGIO^ (containing 400 jil 
IM-NaHSO^/l) using a mini-drill as homogeniser (Expo Drills),' The 
volume of O.IM-HGIO^ was made up to 500 pi and the tubes centrifuged 
at 10,000 g for 2 minutes at 20°G in the bench centrifuge 
(Eppendorf 5412), 100 pi aliquots of supernatant and pellet extract 
were assayed for dopamine using the HPLG-EG method.
Release was expressed as:
________ ngPA in supernatant__________  x 100^
ngDA in supernatant + ngDA in pellet 
= S X 100^
S + P
= Percentage release 
Percentage release was plotted against time.
2.4.4 Release of exogenous | ~ [ -  dopamine
The release of [?h] - dopamine was followed in three ways;
The filtration assay involved incubating tissue in liquid filtration 
cartridges (Millipore S.A., Molsheim, France) for both uptake and 
release and terminating the reaction by using air to force the liquid 
through the nitrocellulose filter supporting the tissue.
In the perfusion assay the tissue, pre-loaded with P n J  - dopamine, 
was continuously bathed in incubation medium and samples of perfusate 
collected in scintillation vials.
In the centrifugation-terminated assay, release was allowed to take 
place in microcentrifuge tubes and was terminated by centrifugation. 
Supernatant was removed from each tube and radioactivity determined by 
liquid scintillation counting.
These different assay procedures were all applied to the tissue-cube 
preparation. Only the centrifugation-terminated assay was applied to 
the crude synaptosome preparation. The details of each assay are 
given below,
2.4,4»! Filtration assay
200 jil aliquots of nucleus accumbens tissue cube suspension (5 pairs 
of nuclei accumbens/ml) in 5iîiM-HEPES buffered saline, pH 7.4 
(containing 5niM-KGl and lOjig bacitracin) were placed on nitrocellulose 
filters (Schleicher and Schüll GmbH, Dassel, F.R.G,, pore diameter 
0.2 |im, filter diameter 13 mm) in plastic liquid filtration cartridges 
(Millipore).
The saline was forced through the filter by air and replaced by 200 jil 
of the same solution containing 2jiGi 7»8- ^ hJ - dopamine (2.3 x 10""^M 
dopamine) , The tissue was incubated for 30 minutes at 20*^ 0 and 
uptake was terminated by using air to force the incubation medium 
through the filter. The tissue was washed three times with 5 ml of saline,
63
The tissue was incubated for 20 minutes at 20°G with 200 jil of 
5 mM-HEPES buffered saline, pH containing 5 mM-KGl and 
50 jig bacitracin/ml t 10"^M TRH, Release of - dopamine was
terminated by using air to force the solution through the filter 
into scintillation vials, (Sterilin Ltd., Teddington, Middlesex, U.K.) 
and radioactivity determined by liquid scintillation spectrometry. 
Pellets of tissue were placed with the filters in scintillation vials 
for determination of radioactivity.
Release was expressed as:
Counts per minuts (GPM) in supernatant x 100^
GPM in supernatant + GPM in pellet
_$___ X  100^
S^P
04
2.4.4.2 Perfusion assay
A suspension of tissue cubes from four pairs of nuclei accumbens 
(40-50 mg wet weight) in 400 jil 20 mM-TRIS buffered saline, pH 7.4 
containing 5mM-KGl and 20 ug bacitracin were incubated in a test-tube 
(Gorex Ltd) with 4 jiGi -dopamine (2.3 % 10"'^ M dopamine) at
37°G for 30 minutes with shaking.
Following incubation, 200 jil of suspension was placed in two
liquid filtration cartridges (Millipore) with nitrocellulose filters
n
(pore size 0.2 |im, Schleicher and Schull) and the solution forced 
through the filters by air.
The cartridges were connected to a peristaltic pump (Technicon Ltd., 
London, U.K.) and immersed in a waterbath at 37°G. The tissue 
perfused at a rate of 0.5 ml/minute with 20 mM-TRIS buffered saline, 
pH 7-4 or pH 6 .5 containing 5 mM-KGl and 50 pg bacitracin/ml at 
37°G pre-gassed with 95^ 0^, %  GO^.
Initially, 0.5 ml samples of perfusate were collected in scintillation 
vials and radioactivity determined until a steady basal release was 
obtained. The saline perfusing the tissue in one of the cartridges 
was then changed for 20 mM-TRIS buffered saline, pH 7.4 or 6.5, 
containing 50 pg bacitracin/ml and 50 mM-KGl, 50 mM-KGl-plus-lmM- 
tyramine or 0.5mM-TRH. Perfusion with this saline continued for the 
duration of the experiment and samples were collected every minute in 
scintillation vials for determination of radioactivity.
Tissue pellets on filters were placed in vials for determination of 
■ the radioactivity remaining in the tissue.
Release at each time-point was calculated by taking the GPM at that 
point to be GPM supernatant and the total of all the GPM in subsequent 
samples, plus the GPM in the final pellet, to be GPM pellet for that point
h, ^
Release was expressed as a percentage, as for the filtration assay. 
Stimulation of release due to treatment with 50 mM-KGl, 50 mM-KGl- 
plus-lmM tyramine or 0.5 mM-TRH was calculated ty summing, the 
percentage release over a period of basal release (SUM control) and 
over an equivalent period during treatment )
(Figure l4) Percentage stimulation was calculated thus;
SUM stim X 100^
SUM control
Figure l4 Calculation of percentage stimulation of release during 
perfusion assay (Example only)
o
o
X
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T i  m e (mi n )
SUMcontrol = sum of percentage release over period of x minutes 
before stimulation
SUMstim = sum of percentage release over equivalent period x minutes
after the start of stimulation.
Percentage stimulation = SUMstim x 100%
SUMcontrol
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2.4.4,3 Centrifugation - terminated assay 
2.4.4.3a) Synaptosomes
200 |il of "SI" supernatant of nucleus accumbens or striatum were 
diluted 10-fold with 20 mM-TRIS buffered saline, pH 7*4, containing 
5 mM-KCl and 50 jig bacitracin/ml, and incubated for 30 minutes with 
4 jiGi [^h'J-dopamine (4.5 x lO'^) at 37°C with shaking.
Uptake was terminated by centrifugation at 10,000 g for 15 minutes 
at 4^C in an MSE 18 centrifuge (Measuring and Scientific Equipment Ltd., 
London, U.K.). The pellet (P2 fraction) was resuspended in 5 ml 
20 mM-TRIS buffered saline, pH 7*4, containing 5mM-KCl and 50 jJig 
bacitracin/ml and recentrifuged at 10,000 g for 15 minutes at 4°C.
The resulting pellet was washed three times by resuspension in 5 ml of 
the same saline followed by centrifugation at 10,000 g for 15 minutes 
at 4°C.
The washed pellet was resuspended in 3-4 ml of 20mM-TRIS buffered 
saline, pH 7.4 or 6.5, containing 5 mM-KCl and 50 jig bacitracin/ml at 
0°C.
100 |il aliquots of this suspension (0,05-0.07 mg protein) were added 
to Eppendorf microcentrifuge tubes at 37°G containing 20 jil of the 
same saline, with 300 mM-KCl, 300 mM-KCl-plus-6 mM-tyramine or 
6mM-TRH at pH 7*4 or 6.5.
Release was allowed to continue for up to 4 minutes and was terminated 
by immersion of the tubes in ice-water and addition of 500 jil ice-cold 
20mM-TRI8 buffered saline, pH 7*4 or 6,5 containing 5mM-KCl and 50 jig 
bacitracin/ml. The tubes were- then centrifuged at 10,000 g for 
2 minutes at 4^G in the Eppendorf bench centrifuge.
500 jil of supernatant were removed from each tube and added to 
scintillation vials (Sterilln Ltd), The remaining 100 jil were aspirated 
using an intravenous cannula (portex Ltd., Hythe, U.K.).
oo
Pellets were homogenised in 100 jil O.IM-HGIO^ using a mini-drill 
(Expo Drills Ltd) with a teflon-tipped pestle as the homogeniser.
The volume of O.IM-HGIO^ was* made up to 600 |il and the tubes 
centrifuged at 10,000 g for 2 minutes at 20°G in the Eppendorf 
bench centrifuge. 500 jil of the supernatant were removed to determine 
the radioactivity by scintillation spectrometry and the remaining 
100 jil were aspirated using a cannula.
The pellets were dissolved overnight in 500 jil 2% SDS in O.lM-NaOH 
and 100 jil aliquots of the solution taken for protein determination,
2.4.4,3 b) Tissue cubes
Tissue cubes of rat nucleus accumbens and striatum were incubated with 
1 jiGi J - dopamine/ml (2 pairs nuclei accumbens; 16-24 mg wet weight/ 
ml or a half-pair striata; 20-30 mg wet weight/ml) in 20 mM-TRIS 
buffered saline, pH 7,4, containing 5mM-KGl and 50 jig bacitracin/ml, 
at 37°C with shaking for 30 minutes. Following incubation, uptake was 
terminated by centrifugation at 10,000 g for 10 minutes at 4^G in the 
MSE 18 centrifuge.
The tissue was washed., three times by resuspension in 5 ml 20 mM-TRIS 
buffered saline, pH 7*4, containing 5mM-KCl and 50 jig bacitracin/ml 
and recentrifugation at 10,000 g for 10 minutes at 4*^ 0 in the MSE 18 
centrifuge,
The tissue was resuspended in the same saline (600 jil/nucleus accumbens 
or 2.4 ml/striatum, final volume 9-12 ml) and dispensed in 600 jil 
aliquots into Eppendorf Microcentrifuge tubes at 0°G. The tubes were 
centrifuged at 10,000 g for 2 minutes at 20°G in the Eppendorf bench 
centrifuge. Following centrifugation the supernatant was aspirated 
from each tube except for the zero-time incubations, from which 500 jil 
of supernatant was transferred to scintillation vials.
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To the other tubes was added 600 jil 20mM-TRIS buffered saline, pH 7,4 
or pH 6.5, containing 5mM-KGl (control) or 50 mM-KGl in the absence 
and presence of either O.lmM-TRH or 0.1mM-GG3703 and 50 jig bacitracin/ml, 
pre-warmed to 37°0.
The tubes were incubated for 5 minutes at 37°0 with frequent wrtexing 
to suspend the tissue.
Release of j^H^-dopamine was terminated by immersion of the tubes in 
ice-water followed by centrifugation at 10,000 g for 2 minutes at 20°G 
in the Eppendorf bench centrifuge, 500 jil aliquots of supernatant were 
transferred to scintillation vials to determine the released radio­
activity by scintillation spectrometry. '
The pellets were treated to extract the j^H^-dopamine remaining in 
the tissue as for the P2 preparation. The volume of 0 .IM-HGlOj^  was 
made up to 600 jil with 0,1 M-HGIO^ and the tubes centrifuged at 
10,000 g for 2 minutes at 20^G. 500 jil aliquots of the supernatant 
were transferred to scintillation vials to determine the retained 
radioactivity by scintillation spectrometry.
The pellets were dissolved overnight in 500 jil ^  (w/v) SDS in O.IMNaOH 
and 100 jil aliquots taken for protein determination.
ru
2.4.4,4 Ga^-dependence of K~** stimulation of release of dopamine
a) Tissue cube preparation
Six rat striata were chopped individually (50-60 mg wet weight) into 
tissue cubes and incubated in 1 ml 20 mM-TRIS buffered saline, pH 7,4 
containing 5mM-KCl, 1 ji Gi [^H ] -dopamine and either 2mM-EGTA or 
0.5mM - 2.5 mM-GaClg at 37^G with shaking for 30 minutes.
The procedure following uptake was the same as the routine assay for 
dopamine release terminated by centrifugation.
b) Synaptosome (P2) preparation
200 pi aliqppts, of SI supernatant (1.7 mg protein) from 4 pairs of 
rat striata were diluted with 1.8 ml of 20mM-TRIS buffered saline, 
pH 7.4 containing 5mM-KGl, 4 pGi [^H J -dopamine and either 2mM 0GTA 
or 0.5mM-2,5mM-GaGl^ and incubated at 37°G with shaking for 30 minutes. 
The procedure following uptake was the same as the routine assay for 
dopamine release terminated by centrifugation.
Tissue from each incubation was kept.in the same CaGl^ concentration 
throughout, 50mM-KGl was used to stimulate release. p H ^  -dopamine 
released was determined by liquid scintillation spectrometry. 
Percentage release was plotted against GaCl^ concentration.
2.4,5 Acetylcholine release assay
Tissue cubes of nucleus accumbens or septum (90-120 mg wet weight) 
were Incubated in 20mM-TRIS buffered saline pH 7.4 (50 mg tissue/ml) 
containing 5mM-KGl, 50 jog bacitracin/ml and 0.ImM-physostigimine with 
^Ëj-choline chloride (lO |iGi/ml) in a 10 ml test tube (Gorex Ltd) 
at 37°G with shaking for 30 minutes.
Termination of uptake and the washing procedures were the same as 
those used for the loading of tissue cubes with dopamine,
Gonditions of release were the same as those used in the release of 
dopamine from tissue cubes and the assay was terminated by 
centrifugation at 10,000 g for 2 minutes at 20^G in the Eppendorf 
bench centrifuge. The proportions of acetylcholine and choline in the 
supernatant and pellet fractions were determined as follows;
100 pi aliquots of supernatant were placed in scintillation vials and 
the total radioactivity measured by liquid scintillation spectrometry 
400 pi aliquots of the 500 pi remaining in each tube were transferred 
to other microcentrifuge tubes and freeze-dried overnight.
After freeze-drying the residue in the tubes was dissolved in 50 pi 
methanol containing lOmM-Gh and lOmM-AGh as markers. The proportion 
of radioactivity in 10 pi aliquots was determined following chromato­
graphy on cellulose TLG plates (Merck, without fluorescent indicator), 
which were developed for about 6 hours in butan-l-ol/water/ethanol/ 
glacial acetic^acid solvent (8 ; 3 : 2 : 1 by volume). The plates 
were dried under warm air and sprayed with freshly prepared 
iodoplatinate reagent, made by mixing 20 volumes of 4.5^ (w/v) KI in 
ethanol/water (l : 1 v/v) with 1 volume of 3% (v/v) chloroplatinic
acid, to locate the marker Gh and AGh.
The regions of the plate corresponding to marker Gh and AGh were 
transferred to scintillation vials for determination of radioactivity 
by liquid scintillation spectrometry, 3 ml of Toluene PPO/Triton X-100 
scintillation fluid was added to each vial followed by 1.4 ml of 
distilled water to produce a gel. The vials were shaken vigorously 
to suspend the particles of cellulose in the gel.
The pellets were homogenised in 15O pi of methanol, containing lOmM-GH 
lOmM-AGh as markers, using a mini-drill (Expo Drills Ltd) with a 
teflon-tipped pestle as homogeniser and were stored at -20°G for 
30 minutes. The tubes were centrifuged at 10,000g for 2 minutes at 
20°G and 100 pi of the supernatant taken for liquid scintillation 
spectrometry. The proportions of Gh and AGh in 10 pi aliquots of 
the pellet extract were determined following chromatography on cellulose 
TLG plates as described above.
The GPM in the aliquots of supernatant and pellet extract not
subjected to chromatography were corrected to their original volumes thus!
GPM TOTALSupernatant GPM
ALIQUOT
Supernatant X 6
and GPM TOTALPellet GPM
ALIQUOT
Pellet X 1 .5
TOTAL
The GPM contributed to the GPM in each fraction by Gh and AGh was
determined using the proportions found on the TLG plates so that AGh 
release could be related to the total AGh content of the tissue and 
Gh release could be related to the total Gh content of the tissue. 
Figure I5 shows a typical separation of Gh and AGh on the cellulose TLG 
plates in butan-l-ol/water/ethanol/glacial acetic acid solvent.
Figure 15 ! Separation of Choline and Acetylcholine on Cellulose
TLG plates
-  Soivent , f r o n t
ACh
O r i g i n
Solvent : Butan-l-ol/water/ethanol/glaclal acetic acid. 
(8:3;2:1, ly volume)
Rf values Choline (Gh) 0 .33-0 .0 1 (n=8)
Acetylcholine (AGh) 0.43-0.02 (n=8)
2.5 Scintillation spectrometry (Turner, 1969)
Supernatant ( 400-500 jil ) or pellet extract ( 100-500 jil ) containing 
^ -dopamine or -choline or acetylcholine was placed in
polythene insert-type scintillation vials (Sterilin Ltd., Teddlngton, 
Middlesex, U.K.), 3 ml of scintillation fluid, toluene/Triton X-100
(2 : 1 v/v) containing 0,8% (w/v) diphenyloxazole (PPO) was added and 
the vials capped and shaken to disperse the samples.
Radioactivity in each vial was determined using a liquid scintillation 
counter (Packard Tri-Garb 3255» Hewlett Packard Inc., Illinois, U.S.A. ; 
Beckman LS 6800, Beckman Instruments Ltd., High Wycombe, Bucks., U.K. ; 
or Intertechnique SL 4000 PG 4000, Intertechnique Ltd., Uxbridge, 
Middlesex, U.K.). Counts were recorded for 4 minutes with no sub­
traction of background and expressed as the mean of the counts per 
minuts (gPM). Counting efficiency was about 30% for ^H and about 
50% for ^^G (Table 4 ).
Table 4
q IZj,
Efficiency of counting of H and G
Isotope jjGiCounted DPM GPM
Efficiency 
GPM/DPM X 100^
10-2 22200 6771 3 0.5
10-2 22200 6882 31 .0
10-2 22200 7659 34 .5
10-2 22200 7770 35 .0
10-2 22200 7437 33 .5
10-2 22200 7881 35.5
10-2 22200 6438 29.0
10-2 22200 5994 27.0
Mean - SD
3 2 .0 Î 3 .1
2 X 10-3 4440 2124 4 7 .8
2 X 10-3 4440 2183 49 .2
2 X 10-3 4440 2142 48.2
2 X 10-3 4440 2124 47 .8
2 X 10-4 444 207 45 .9
2 X 10-4 444 216 48.6
+
Mean - SD
47 .9 - 1 .1
ru
2.6 Preparation of quench curve
Cellulose TLG plates, without fluorescent indicator (Merck) were 
loaded with 18 x 50 jil samples of -choline (2.5 x lO^DPM) in
methanol containing choline (lOmM) and acetylcholine (lOmM) as markers.
The plates were developed for about 6 hours in butan-l-ol/water/ethanol/ 
glacial acetic acid solvent (8 ; 3 : 2 : 1 by volume) and dried under 
warm air. The dry plates were sprayed with iodoplatinate reagent and 
the region of the chromatogram corresponding to Gh and AGh transferred 
into scintillation vials. 3 nil toluene-PPO/Triton X-100 (2 : 1 v/v) 
scintillation fluid was added to each vial with up to 1.6 ml distilled 
water. The vials were shaken vigorously to suspend the particles of 
cellulose and radioactivity determined by liquid scintillation spectrometry 
Quenching was expressed as an H-number (H * ), which is the difference 
between the maximum pulse height produced in each sample by the 
-emissions of an external standard (^37qq  ^ and the maximum pulse 
height, caused by the same external standard, in an unquenched sample, 
a value preprogrammed into the scintillation counter, on an arbitrary 
scale of 0 to 1000.
Gounting efficiency was calculated for each sample as:
™  X 100#
DPM
Gounting efficiency was plotted against H-number and ml H^O as shown
in Figure l6.
Figure l6 ; Determination of efficiency of scintillation counting of
H -choline on particles of cellulose suspended in a
toluene-Triton X-lOO/water gel
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2.7 Protein estimation
Protein was estimated in tissue pellets try a modification of the 
method of Lowry et al(l95l).
Pellets of tissue (4-6 mg wet weight) were dissolved in 500 yil of 
2^ 0 (w/v) SDS in O.IM NaOH overnight. 100 jil aliquots of solution 
were taken in duplicate for protein estimation and placed in test 
tubes. To each tube was added 3 ml of solution C (prepared by 
mixing 50 ‘ml of 2^ (w/v) anhydrous Na^ 00^'and 0.2^ (w/v) SDS in 
0 .IM NaOH (Solution A) with 1 ml of 0.5^ OuSO^ 5Hg,0 in 1^ (w/v) 
trisodium citrate) (Solution B) and, after 10 minutes, 0.5 ml of 
Folin-Giocalteau reagent, diluted 1 : 2 (v/v) with water.
The absorbance (A^^q) of the samples was determined using a Beckman 
Dual Beam spectrophotometer (Beckman Ltd) after at least 30 minutes 
of colour development. Absorbance was read against a protein 
calibration curve (0-100 jig protein) using bovine serum albumin 
as a standard (Fig.l?),
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2.8 Statistics
Statistical significance was determined try the Student t-test.
The factor t, the significance of deviation of a statistic from zero, 
was calculated ty using the formulae:
S = / (tij_ - 1) + (rig - 1)
and
% / -  " -V  î^i %2
where
S = mean of standard deviations of populations 1 and 2
^1* ^2 ~ standard deviation of population 1, 2
n^, Ug = number of values in population 1, 2
x^, Xg “ mean of values in population 1, 2
(n^ + n2 )-2 - degrees of freedom
The probability of an effect happening ty chance was found by entering 
the t-value into the t-distribution significance table (Pollard, 1978) 
at the required degree of freedom.
Ill RESULTS
Results
3.1 Characterisation of some regions of rat train
Regions of rat train corresponding to the nucleus accumbens, corpus
striatum and hypothalamus were dissected as described in Materials
and Methods, The wet weights of these regions, 12.29 - 2.22 mg
(n = 14) for the nucleus accumbens, 60.25 - 13.80 mg (n = 18) for
the corpus striatum and 6?.80 - 6.20 mg (n = 4) for the hypothalamus,were
in agreement with the corresponding values found in the literature
(Table 5).
Dopamine content of the nucleus accumbens, corpus striatum and 
hypothalamus respectively was; 6084.4 - 896.9 ng/g (n = 8), 4499.2 - 
546.4 ng/g (n = 8) and 366 .6 - 84,0 ng/g (n = 4) and their 
noradrenaline content was 886.9 - 457-9 ng/g (n = 8), 247.3 - 
64,6 ng/g (n = 8) and 2383.6 - 96.0 ng/g (n = 4). These values are in 
agreement with the corresponding values found in the literature 
(Tables 6 and ?) and provide additional evidence that the correct 
brain regions were dissected,
3.2 Release of dopamine from in-vitro preparations of rat brain regions
3 .2 .1 Release of endogenous dopamine from tissue cubes of nucleus accumbens 
Incubation of tissue cubes of rat nucleus accumbens in TRIS buffered 
saline, pH 7^4, containing 5mM-KGl, for 30 minutes at 37^0,caused an 
increase in the release of endogenous dopamine from 15.0^ to 22.3^. 
Incubation in TRIS buffered saline, pH 7.4, containing 50mM-KGl, 
stimulated the release of dopamine from 15.0^ to 3 0.0^ in 10 minutes 
and to 3 8.5^ in 30 minutes, (Figure 18).
This preliminary result showed that the release of dopamine during 
the linear portion of the time-course, in the presence of 50mM-KGl, 
was about 8 ng/500pl sample (-1.6 ng/lOO pi aliquot injected onto 
the HPLG column).
Table 5 : Weight of brain regions
Region
+
Weight (mg, mean - SP) Author
Nucleus 10,90 + 0.40 n = 30 Wilk and Click 1976
Accumbens 12.29
+
2.22 n = 14 This study
23.50
+
1.10 n = 27 Horn et al 1974
Striatum 50.40 - 2.30 n = 30
60.25 ^13.80 n = 18
102.0 -17.0 n = 20
Wilk and Click 1976 
This study
Glowinski and Iversen I966
Hypothalamus 67.80 - 6,20 n = 4
110
+
- 14 n =20
This study
Glowinski and Iversen I966
04-
Table 6:DA Content of nucleus accumbens, striatum and hypothalamus
Region ng DA/g wet wt. - SD Author
Nucleus 4500 + 370 n = 3 Horn et al 1974
Accumbens 6084
+
896.9 n = 8 This study
8420
+
519 n = 9 Oke et al 1978
Striatum 3800 - 360 n = 5 Metcalf 1974
4230
+
50 Friedman et al 1973
4499*2 - 546,4 n = 8 This study
5470 - 1870 n =12 Gordon and Shellenberger 1973
+
7112 - 1620 n =14 Shellenberger and Gordon 1971
+
8070 - 920 n = 5 Coyle and Henry 1973
+
11500 - 430 n =15 Shellenberger 1971
15684 - 1419 n = 9 Oke et al 1978
+16782 - .386 n = 6 Holtzman 1974
Hypothalamus 260 + 20 n =15 Shellenberger 1971
320 30 n = 6 Metcalf 1974
366 ,6 + 84.0 n = 4 This study
370 + 42 n = 9 Oke et al 1978
580 - 100 n = 5 Coyle and Henry I973
Table 7 ; NA content of nucleus accumbens, striatum and hypothalamus
Region ng NA/g wet wt.
+
SD Author
Nucleus accumbens 516 H* 168 n = 9 Oke et al 1978
886.9
+
457.9% = 8 This study
Striatum 6o + 10 n =15 Metcalf 1974
120
+
10 n = 15 Shellenberger 1971
247.3
+
64.6n = 8 This study
250
+
30 n = 6 Glowinski and Iversen I966
300 + 90 n = l4 Shellenberger and Gordon 1971
320
+
120 n = 12 Gordon and Shellenberger 1974
350
+
200 n = 5 Coyle and Henry 1973
Hypothalamus 1070
+
110 n = 15 Shellenberger 1971
1370
+
50 n = 60 Holtzman 1974
I6l0 160 n = 9 Metcalf 1974
1620 + 185 n = 9 Oke et al 1978
1790
+
100 n = 6 Glowinski and Iversen I966
1840
+
20 n = 8 Friedman et al 1973
i960 + 100 n = 5 Coyle and Henry 1973
2383.6 + 96.On = 4 This study
Figiire 18 : Time-cour sa of release of endog.eriaus dapamine from
tissue cu'bes of rat nucleus accum'bens in THIS "buffered saline, pH?.4 
followed by sampling from a single incubation vessel.
o
- s
o
moU~l
o o oo
07
This was too close to the limits of detection of the home-made 
electrochemical detector which was used at the beginning of this 
project to enable further work on release of endogenous dopamine 
to be carried out with confidence. It was therefore decided to 
concentrate on studying the release of ( H)-dopamine from pre- 
loaded tissue preparations,
3*2.2 Metabolic viability of tissue cubes
The rate of oxygen uptake ty tissue cubes of rat nucleus accumbens 
was not affected ty the incubation and washing procedures used
O
during the pre-loading of tissue with ( h)-dopamine (Table 8). 
50mM-KGl was found to stimulate ( H)-dopamine release ty 92^ in 
the unwashed sample and 183^ in the washed sample. The similarity 
between oxygen uptake before and after washing and the stimulation 
of Og uptake ty 50 mM-KGl after washing suggests that the tissue was 
damaged very little ty the pre-loading procedure.
The absolute values of 0^ uptake obtained are lower than those 
reported for rat cerebral cortex, tissue cubes ty Mcllwain and 
Buddie (1952)1 who found rates of uptake of about InmolO^/min/mg 
tissue. The stimulation of 0^ uptake observed in the nucleus 
accumbens ty 50 mM-KGl was about the same as that observed ty 
Mcllwain and Buddie on electrical stimulation of cerebral cortex 
tissue cubes.
3 ,2,3 Release of exogenous dopamine , . , .
a)Filtration assay
Previous work (Shapiro et al (198O)) suggested that TRH (10“^M)
o
stimulated the release of (H)-dopamine from P2 preparations of rat 
striatum. Thus, 10 ^M TRH was used in initial studies with tissue 
cubes of rat nucleus accumbens.
Table 8 i Effect of washing procedure on the metabolic rate of nucleus 
accumbens tissue cubes
Og uptake n mol Og/min/mg tissue
Basal K- stimulated
(ft. of tissue (mg) Pre-wash Post wash Pre wash Post wash
39.8 0.130 0.169
37.2 0.139 0.448
38.0 0.146 0.289
21.2 0.103 0.285
31.4 0.105 0.274
34.4 0,107 0.250
H*
Mean - SD 0 .127^0.021 o . i i6 Îo .o § o * 0,244^0.065
+ ^ 
0 .328- 0 .105*
* NS a wrt pre-wash basal rate
b wrt pre-wash K- stimulated rate
TRH (IO^^M) had a variable effect on the release of (^H)-dopamine,
(Table 9),
The ratio; release in presence of TRH (T)
release in absence of TRH (g )
ranged from 0,84 to 1.55 between experiments.
Possible reasons for this variability are:
i) Inhomogeneity of the tissue preparations,
ii) Variations in the reuptake of released (^ H) dopamine
during the asgay.
iii) Variation in the extent of TRH degradation,
b)Perfusion assay
The perfusion assays were carried out in order to reduce possible
variations in release caused by reuptake of the (^H)-dopamine.
The HEPES buffered saline was changed for 20 mM-TRIS buffered saline
because Shapiro et al (198O) found a consistent effect of TRH in
this saline.
Perfusion of rat nucleus accumbens tissue cubes with TRIS buffered 
saline, pH 7.4, containing 50mM-KGl,stimulated (H)-dopamine release.
The peak produced was of shorter duration than the perfusion time 
with 50mM-KGl and the release returned to the baseline after 
3 minutes (Figure 19. lower trace) 50mM-KGl stimulated ( H)-dopamine 
release by about 50^ (Table 10) stimulation of release was 
calculated as described in Materials and Methods,
Perfusion with 50mM-KGl-plus ImM tyramine in TRIS buffered saline, 
pH 7 .4 caused an immediate stimulation of (^H)-dopamine release.
The peak of release was about 4 x higher than that produced by 50 mM-KGl 
alone and took longer to return to the baseline although its decline 
began after the same period as for the 50 mM-KGl peak, (Figure 191 
upper trace),
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Table 9 : Effect of TRH (lO M) on the release of ( H)-dopamine from tissue
cubes of rat nucleus accumbens In KSPES buffered saline pH 7.4 
using the filtration release assay.
Control 10‘ ÏHH
GPM In CPM in c CPM in CPM in 0 TRH
Supernatant P e lle t ('/9tP)xlOO^ Supernatant P e lle t ( ' /S+P)xlOO^ Control
5780 28243 16.99 3250 20875 13.47
4512 33170 11.97 3499 I 8861 15.65
5707 11940 32.34
2O.43i lO .6l
5548 19001 22.60
I 7. 24i 4.77 0.84
51822 187943 21.61 55660 182202 23.40
38048 286215 11.73 34326 241130 12.46
57081 207021 21.61 68971 247413 21.80
66489 184438 26.49 
20.36i 6.20
76093 172065 30.66 
22.08-7.50 1.08
11965 30189 28.38 13152 24018 35.38
16382 41874 28.12 14208 29060 32.84
18157 35972 33.54 
30.o i i  3.06
16425 33505 32.90
33. 7i i l .45 1.12
31239 163038 16.08 27236 96147 22.07
24950 117416 17.56 33059 99546 24.93
22934 165780 12.15
15.26i 2.79
12574 40379 23.74
t
23. 58- 1.43 ‘ 1.54
53970 175585 23.51 85315 173860 32.92
47180 193053 19.64 69588 136915 33.70
44007 165096 21.05 75645 115876 39.50
79478 99362 44.44
27. i 6i 11.63 -
71942 42774 62.71
42 .2o il3 .98 1.55
f p < 0 .0 2 5  W.r. t  37°G Control
Figure 19 ; Effect of jOmjypCGl and jOmMKGl-plus-lmMtyramlne on the
release of ^H-douamlne from a tissue cube preparation of rat nucleus
23 à.ccuml3ens using the perfusion assay in TRIS buffered saline,
50mM KCI -p lu s -  
ImM tyramine
O  50 mM KC
o
o
CL
10-
Q_
St imulat ion
T im e  ( m i n)
Table 10 3.Stimulation of release of H-dopamine from tissue cubes of rat 
nucleus accumbens by 5Qn^ KQl in TRIS buffered saline, pH 7.4 
as followed by the perfusion assay.
Summed S x 100% 
Percentage Release S+P Ratio
-K+ Baseline +K+ Peak Peak/Baseline
11.0 19.2 1.74
9.8 13.7 1.40
8.0 10.0 1.25
9.6 14.3 1.48
11.0 17.9 1.63
11.7 19.4 1.66
13.9 21.2 1.52
22.3 33.9 1.52
Mean - SD 1.52^0.15
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Perfusion with 50 mM-KC1-plus-ImM tyramine caused a consistent 
stimulation of release of between 300% and 800% basal release of 
(^H)-dopamine (Table ll).
Kerwin and Pycock (l979) found a stimulation of (^H)-dopamine 
release from tissue cubes of rat nucleus accumbens using 0.025niM- 
O.lmM TRH. In an attempt to produce a consistent stimulation, the 
mechanism of which could then be studied, 0,5 mM TRH was used in 
these assays.
No stimulation of (H)-dopamine release was observed in the presence 
of 0.5mM TRH at pH 7.4.
At pH 6.5I however, stimulation of (^H)-dopamine release by 0.5 mM-TRH 
was observed (Figure 20).
Subsequent studies showed that G.5mM TRH caused a consistent 
stimulation of (^H)-dopamine release of about 20% at pH 6.5 (Table 12^. 
This finding agreed with previous work by Shapiro et al (l980), who 
reported a greater stimulation of release of (^H)-dopamine from 
striatal P2 preparations at pH 6,6 than at pH 7.2.
TRIS (2-amino-2 hydroxymethylpropane-l,3-diol) has a pKa of 8,6 so 
its buffering capacity below pH 7.0 is very low. It was therefore 
necessary to change the buffer system before studying the effect of
O
TRH on ( h)-dopamine release over a pH range of 6,0-7.4. It was
not possible to use phosphate buffers owing to the requirement for 
Ga^ ions in the perfusion medium so imidazole (pKa 7.0) and HEPES 
(pKa 7.55) were used.
When 20mM-imidazole, pH 7.4, replaced the TRIS, a slight inhibition,
o
approximately 20%, of ( H)-dopamine release was observed. At pH 6.5, 
apart from in one experiment where 7 ^  stimulation of release was
Q
observed, no effect of TRH on ( h )-dopamine was observed, (Table 13).
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Table 11 3.Stimulation of release of H-dopamlne from tissue cubes of rat 
nucleus accumbens by 50 mM KGl-plus-lmM-Tyramine in TRIS 
buffered saline, pH 7.4 as followed by perfusion assay.
Summed S x 100% 
Percentage Release S+P Ratio
Baseline Peak Peak/Baseline
21.5 58.3 2.71
12.6 100.9 8.00
6.4 20.4 3.18
Mean-SD 4 .63-2.90
Figure £0, : Effect of. .TBHC5x1Q~. R). ,021 tJaa xelea^e of. H-dopamine
froa a tissue cube preparation of rat, nucleus, acc.um'bens using the 
perfusion assay in TRIS buffered saline.pH?.and pH6.5.
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Table 12
o
Effect of TRH (5xlO~ M) on release of H-dopamine from tissue 
cubes of rat nucleus accumbens as followed try continuous 
perfusion in TRIS buffered saline at pH 6,3 and pH 7.4.
pH
Summed 
Percentage Release
S X 100^ 
Stp Ratio
-TRH Baseline -KTRH Peak Peak/Baseline
7.4 14.7 15.3 1.04
14.0 15.1 1.07
12.2 12.1 0.99
1.03^0.04
Mean-SD
6.5 16.5 21.3 1.29
8.4 9.9 1.17
9.0 10.7 1.19
6.8 8.3 1.21
I.21Î0 .0 5
Mean-SD
pH 7A  V pH 6.5 p <  0,005
Table 13
—Il Q
Effect of TRH (5xlO“ M) on release of H-dopamlne from tissue
cubes of. rat nucleus accumbens as fallowed by continuous
perfusion in imidazole buffered saline at pH 6.5 and pH 7.4.
pH
Summed 
Percentage Release
S X 100^
S+P Ratio
-TRH Baseline +1'RH Peak Peak/Baseline
7.4 11.5 9.6 0.83
4.1 3.2 , 0.76  
0 .7 9 - 0 .05
M ean - Range
6,5 7.2 7.7 1 .07
14.4 12.4 0,86
10.0 10.1 1.00
6.2 6.0 0.97
3.7 3.6 0.98
8.5 15.0 1.75
1.10 Î 0 .3 2  
+
Mean - SD
9b
Perfusion with 5mM-HEPES buffered saline, pH 6.5, containing 0,5niM-TRH 
produced variable results ranging from 22^ inhibition to 32^ stimulation 
of (^H)-dopamine release (Table 14),
In conclusion, 0.5mM-TRH caused a small but consistent stimulation 
of release of (^H)-dopamine from tissue cubes of nucleus accumbens at 
pH 6.5, but not at pH 7.4, in TRIS buffered saline. This effect could 
not be repeated in either imidazole or HEPES buffered salines, which 
were more effective buffers over the pH range of interest.
The perfusion assay had disadvantages in that replicate incubations 
could not be easily performed, the tissue was apt to clog the filters 
and basal release tended to be erratic, making stimulated release 
difficult to quantify accurately. To resolve these difficulties the 
assay procedure was changed to static incubation, terminated by 
centrifugation.
c)Centrifugation-terminated assay of release of (^H)-dopamine from tissue 
cubes of rat nucleus accumbens
Tissue cubes of nucleus accumbens were incubated in TRIS buffered 
saline, pH 7.4, containing either 5mM-KGl or 50niM-KGl for 0-10 minutes 
and a time-course of release of (^H)-dopamine under these conditions 
was obtained (Figure 2l). The ratio:
(^H)-DA release in 50mM-KGl 
(^H)-DA release in 5mM-KGl 
was 1.77 at 5 minutes and 1.86 at 10 minutes. Thus 5 minutes was 
chosen as a suitable time for subsequent assays.
Tissue cubes of nucleus accumbens were incubated with a range of TRH 
concentrations (l0“^-10 “^ M) in TRIS buffered saline at pH 7.4 and 
6.5. At pH 7.4 the results were variable and no clear concentration 
related effect of TRH was observed. At pH 6.5 a concentration-related 
stimulation of (^H)-dopamine release (7-45^) was observed (Table 15).
Table 14
— Il Q
Effect of TRH (5x10 M) on release of H-dopamine from tissue
cubes of rat nucleus accumbens as followed by continuous
perfusion in HEPES buffered saline at pH 6.5.
Percentage Release
S X 100^ 
S+P Ratio
-TRH Baseline +1'RH Peak Peak/Baseline
22.6 17.7 0.78
8.1 10.7 1.32
10.2 9.5 0.93
16.0 17.2 1 .07
10.0 8.8 0.87
12.6 13.5 1.07
17.? 8.9 1.16
+
Mean - SD 1.03 - 0.18
3
Figure -21 ■ . Tj-m.e-.Qoiir.se. of. release of. H-do.pamine. fTom tissue cubes
of rat nuclaus accuiubene .la THIS buffered saline « pH?.4, followed 
the centrifugation terminated release assay.
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The experiment was repeated using the TRH analogue GG3703 
(6-methyl-5“OXothiomorpholinyl-3-car‘bonylhistidylprolineamide),
At pH 7,4; GG 3703 (10~^-10-^M) did not cause any stimulation of 
(^H)-dopamine release whereas at pH 6,5 up to 28^ stimulation was 
observed as the concentration of GG3703 was increased to 10” M 
(Table I6).
In all cases 50mM-KGl caused a stimulation of release of (^H)- 
dopamine release (7^ - 300%) showing that the preparations used 
were viable. The stimulation of release by 50niM KOI was found to 
be dependent on the presence of Ga^^ions (Figure 22). Only a 
small Ga^"*"-independent KGl-stimulation of release of (^H)-dopamine 
was observed (KG1/37°G Gontrol = 1,19) whereas in the presenceof 
Gabions the KGl-stimulation was marked (kG1/37°G Gontrol = I.63) .
The finding suggests that 50mMKGl caused release of (^H)-dopamine 
from within the tissue not by washing (^H)-dopamine from sites of 
adsorption on the surface of the tissue,
d)Gentrifugation-terminated assay of release of (^H)-dopamine from P2 
preparations of striatum and nucleus accumbens
Previous work (Shapiro et al, I98O) showed that TRH (imM) stimulated 
the release of (%)-dopamine from striatal P2 preparations. It was 
decided to examine the effect of TRH on P2 preparations of nucleus 
accumbens in comparison with striatal P2 preparations. An advantage 
of using P2 preparations is that in washed or purified preparation 
there is a very little degradation of TRH (Parker et al, 1977; Shapiro 
et al, I98Oî Biggins et al, I98I).
The presence of intact vesicles in the P2 preparations was determined 
by the presence of occluded lactate dehydrogenase (Table 17).
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Ga -"dependence of KGl stimulation of release ofFigure 22
3^H-do.-panilne .from rat striatum tissue cube preparation in TRIS 
buffered saline,
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Table 1? : Percentage of total LDH activity occluded in P2 preparations
The value obtained agrees with the findings of Johnson and Whittaker (1962) 
who found that about of the LDH activity recovered in the P2 fraction 
was localised in nerve ending particles and released on treatment with 10^ 
(v/v) Triton X-100,
LDH activity ( £i ^340/minute)
Free Total % Occluded
0.023 0.102 77.35
0.012 0.086 86.01
0.007 0.043 84,61
0.003 0.040 91.67
0.007 0.043 84.61
0.017 0.080 79.17
0.023 0.085 72.66
0.013 0.083 84.00
0.013 0.070 80.95
0.020 0.068 70.59
0.013 0.040 66.67
0.015 0.046 67.86
0.010 0,043 76.92
0.017 0.060 72.22
0.010 0 .047 78.57
0.040 0 .154 74.02
"t
Mean-SD 78.00-7.07
The presence of nerve-ending particles was determined by electron 
microscopy (Figures 23. 24 and 25).
The effect of 50mM-KGl and ImM-tyramine on the release of (^H)- 
dopamine was studied in P2 preparations of nucleus accumbens in 
TRIS buffered saline, pH 7.4. Release was terminated by 
centrifugation at 0-4°G (Figure_^) .
At 37°G in the presence of 5mM-KGl release of (^H)-dopamine increased 
linearly from 27^ to hjfo by 4 minutes. No time-dependent release 
could be detected at 0°G, suggesting that the zero-time value of 
represented residual extracellular (^H)-dopamine. 50mM-KCl stimulated 
release by approximately 50^ during the initial 2 minutes, following 
which no further stimulation of release was observed. ImM-tyramine 
stimulated release approximately 150^, too rapidly to be resolved 
in the time taken to terminate the zero-time sample.
In view of the result with 50mM-KGl, subsequent assays with P2 
preparations were incubated for 2 minutes.
TRH (imM) had no consistent effect on the release of (^ H)-dopamine 
from P2 preparations of rat nucleus accumbens and striatum at pH 7.4 
in TRIS buffered saline (Table 18^,
In contrast,5@i#Gl stimulated release approximately 100^ showing that
the lack of response to TRH was unlikely to be the result of damage
to the nerve-ending particles in the P2 preparation procedure.
24"The 50mM-KGl stimulation was found to be Ga -dependent indicating (Fig.27)
3 3release of ^H-dopamine, not washing of H-dopamine from the surface
of the tissue. A 41^ Ga^ **”-independent stimulation of release was observed.
At pH 6.5» TRH (imM) and histidylproline diketopiperazine (imM)
stimulated the release of (%)-dopamine 20^ and 26^ respectively
from nucleus accumbens P2 preparations (Table 19) and 39^ and
respectively from striatal P2 preparations (Table 20).
J.U7
Figure 23 : Electron micrograph of P2 fraction of nucleus accumbens
showing the presence of synaptosomes containing synaptic 
vesicles and mitochondria (indicated by arrows, S).
(X 7,500)
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Figure 24 % Electron micrograph of a single synaptosome showing
limiting membrane (LM), mitochondria (m) and synaptic 
vesicles (v)
(X 50,000)
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Figure 25 : Electron micrograph of a single synaptosome showing the
synaptic cleft (SC), the post-synaptic membrane (PSM) 
and associated post-synaptic density (PSD)
(X 50,000)
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Figure. 26 .Tlma-.cgurse of zialeaaa of ^ H-.do-pamine from a washed 
P.2 -pr.eT^atlon .o£ rat iiucle.ua e^ agumbeiis. In. TEIS. ~buff.er.ed saline 
pH 7.4, followed by the centrifugation terminated release assay.
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3.2.4 Conclusion to the findings of the experiments on dopamine release 
Irrespective of the assay procedure used, TRH, its metabolite 
histidylproline diketopiperazine (cyclo His Pro) and the analogue
o
CG3703 appear to stimulate the release of (H)-dopamine from tissue 
preparations of both nucleus accumbens and striatum over a range of 
concentrations (l0"^-10‘^M TRH, 10“^-10'^M CG3703 and 10”^M cyclo 
HisPro).
The stimulatory effects of these peptides are more clearly seen at 
pH 6 .5 than at pH 7.4.
The largest stimulation of (h)-dopamine release, however, was only 
43^ greater than basal release, caused by 10 M TRH in tissue cubes of 
nucleus accumbens at pH 6.5. In view of the high concentration of
peptide required to produce this relatively small effect it was
decided not to pursue this effect any further and to investigate the
effects of TRH on the release of acetylcholine,
3.3 Acetylcholine release studies
The nucleus accumbens and septum both contain high affinity TRH-binding 
sites (Burt and Snyder, 1975) and are sensitive to TRH in in-vivo 
(Miyamoto et al, I978; Miyamoto and Nagawa, 1979; Heal and Green, 
1979; Kalivas and Horita, I98O) and in-vitro assays (Kerwin and 
Pycock, 1979; Hagai et al, 1980; Sharp et al. I98I). Both regions 
are rich in cholinergic nerve terminals (Jacobow.itz and Palkovits,
1974). Acetylcholine has been reported to stimulate dopamine release 
(Giorguieff et al. 1975; de Belleroche and Bradford, 1978) and TRH 
has been reported to stimulate acetylcholine turnover in rat brain 
tissue preparations (Malthe-S^renssen et al, 1978). Thus a study 
on the effects of TRH on the release of acetylcholine from tissue cubes 
of rat nucleus accumbens and septum was carried out using the 
centrifugation terminated assay.
Sharp et al (198I) reported that O.lmM TRH stimulated release of 
endogenous dopamine from tissue cubes of nucleus accumbens and septum 
at pH 7,4 , If this stimulation were caused indirectly via cholinergic 
systems then these conditions should be suitable to demonstrate TRH 
effects on acetylcholine release. In addition, the effects of cyclo- 
HisPro (O.lmM) and GG3703 (O.lmM) on basal and K**"-stimulated acetylcholine 
release were also studied.
Tissue cubes of nucleus accumbens and septum were preloaded with 
(^H)-choline as outlined in Materials and Methods, In the nucleus 
accumbens 0.703 - 0.148% (mean - SD) of the choline was converted to 
acetylcholine per mg tissue in 30 minutes compared with a 0,218 - 
0.040% conversion per mg tissue in 30 minutes for the septum (Table 2l).
In each case the standard deviation was about 20% of the mean, 
suggesting that these regions were dissected with equal accuracy.
In the preliminary experiments, the effect of ImM-TRH and fOmM-KGl 
on the release of radioactivity from tissue pre-loaded with (^H)-choline 
was studied. No steps were taken to determine the nature of the 
released radioactivity.
50mM-KCl stimulated ^H release by 73 - 308%, ImM-TRH stimulated release 
0- 62% (Table 22).
One possible reason for the variability in the stimulation observed is 
that differing amounts of choline (Ch) might be released with the 
acetylcholine (AGh). It was therefore decided to separate the AGh and Ch 
in the supernatant and pellet fractions so that release of AGh could be 
calculated as a percentage of the AGh "pool" in the tissue. Both Gh and 
AGh were found in the supernatant and pellet fractions and a small amount 
of radioactivity remained associated with the origin. (Table 23).
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The percentage of AGh in the supernatant increased from about 30% 
in the 0°G control to about 60% in the 50 mM-KGl stimulated 
incubation. Total GPM in the Gh and AGh spots increased from about 
40 in the 0°G control to about 200 in the 50 mM-KGl stimulated 
incubation. In the pellet fraction the percentage of AGh dropped 
from about 55% in the 0°G control to about 4 ^  in the 50mM-KGl 
stimulated incubations, the absolute GPM in Gh and AGh falling from 
about 600 to about 400.
No appreciable hydrolysis of AGh to Gh occurred during the freeze- 
drying step in the separation of Gh from AGh (Table 24). Thus the 
Gh present in the supernatant fraction was not formed by hydrolysis 
of AGh during isolation.
The effects of 0.ImM-TRH, 0 .ImM-histidylproline diketopiperazine and 
0.1mM-GG3703 on the release of (^H)-AGh and (^H)-Gh from tissue cubes 
of rat nucleus accumbens and septum were studied in the presence of 
5mM-KGl and 50 mM-KGl.
0,ImM-TRH had no consistent effect on either basal or 50mM-KGl- 
stimulated release of (^H)-AGh (Table 25) or (^H)-Gh (Table 26) from
nucleus accumbens,
50mM-KGl stimulated ( H)-AGh release from nucleus accumbens by up to 
540% and (^H)-Gh release by up to 260%.
0.ImM-TRH had no consistent effect on basal nor 50mM-KGl stimulated 
release of (^H)-AGh (Table 27) nor (^H)-Gh (Table 28) from tissue 
cubes of septum. 50mM-KGl stimulated the release of ( H)-AGh by up
to 1900% and release of (^H)-Gh by up to. 280%.
0 .ImM-cycloHis-Pro had an inhibitory effect, up to 6^, on la sal 
release of (^H)-AGh from tissue cubes of septum in all cases except one,
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when a 6l% stimulation of release was observed (Table 29)• This
Q
dipeptide had no consistent effect on 50mM-KGl stimulated ( H)-AGh 
release, nor on basal nor 50mMKCl-stimulated (^H)-Gh release from 
tissue cubes of septum (Table 30).
0,lmM-GG3703 had no consistent effect on either basal or 50niM-KGl 
stimulated release of (^H)-AGh (Table 3l) or (^H)-Gh (Table 32) from 
tissue cubes of nucleus accumbens,
0.1mM-GG3703 had no consistent effect on either basal or 50inM-KGl 
stimulated release of (^H)-AGh (Table 33) or (^H)Ch (Table 34) from 
tissue cubes of septum.
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3*3«1 Conclusion to the findings of the experiments on acetylcholine and 
choline release
Contrary to the work on acetylcholine release reported in the 
literature (Wonnacott and Marchhanks, 19?6; Wonnacott, I98O), this 
study found that high extracellular KGl concentrations caused the 
release of both ( H)-acetylcholine and ( H)-choline from train tissue 
preparations. The percentage release of (^H)-choline relative to the 
(^H)-choline pool in the tissue was about half that of (^H)-acetylcholine 
relative to the (^H)-acetylcholine pool under depolarising conditions 
caused by 50mM-KGl (Table 35). This value was more consistent in the 
nucleus accumbens than in the septum.
TRH and its analogues (O.ImM) had no significant effect on basal nor 
50mM-KGl stimulated release of either (^H)-acetylcholine or (^H)- 
choline. The ratio release of (^H)-acetylcholine/(^H)-choline was 
unaffected by these compounds.
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IV DISCUSSION
4.1 Scope of thesis
The main aim of this thesis was to study the effect of ÏRH on the release 
of DA and AGh in order to provide further evidence of a role for TRH as a 
neurotransmitter or neuromodulator in the mammalian central nervous system 
(GNS). Before a chemical can be defined as a neurotransmitter, the 
following criteria must be fulfilled:
1. The chemical must be stored in the nerve endings from which 
it is released,
2. It must be released upon pre-synaptic stimulation and 
shown to be present in the extracellular fluid in the 
vicinity.
3. When applied post-synaptlcally it must mimic the action 
seen when the presynaptic system is stimulated,
4. Specific antagonists should be recognised which prevent 
the action of both the chemical itself and electrical 
stimulation.
5. Some mechanism must be present to limit the duration of 
action of the chemical at its post synaptic receptors.
These criteria were originally formulated from evidence for a neurotrans­
mitter role for acetylcholine (Bachelard, 1974) and have been applied to 
other putative neurotransmitters.
Part of criterion (3) was examined for TRH in this thesis : the search
for an effect of exogenously applied TRH on the release of other better 
classified neurotransmitters, to try and obtain biochemical support for 
the hypothesis based on behavioural studies that one action of TRH is to 
stimulate dopamine release and to investigate whether any effect 
observed was direct or via modulation ty cholinergic mechanisms.
1 Lin
The effects of TRH and some of its analogues on the release of dopamine 
from rat nucleus accumbens and striatum and of acetylcholine from nucleus 
accumbens and septum were studied using different tissue preparations and 
release assays. The relative merits of the preparations and assays are 
discussed below, followed by discussion of the results obtained in their 
use.
4.2 Tissue Preparations
4.2a) General
In-vitro tissue preparations are important to the study of the biochemistry 
of the mammalian GNS because they allow the observation of the metabolism 
and release of specific neurotransmitters in specific brain regions, 
which could not be performed in-vivo or in intact brain in-vitro.
Tissue cube or synaptosome (P2) preparations, for example, allow 
neurotransmitter release to be followed directly instead of by inference 
based on changes in metabolite levels in the cerebrospinal fluid, urine 
or plasma.
In-vitro preparations also allow the manipulation of neurotransmitter 
biochemistry so that regulating factors and the effects of the activity 
of one transmitter system on another can be determined.
Tissue cubes and P2 preparations were used in this study.
4.2b) Tissue cubes
Tissue cube preparations may be regarded as very crude homogenates in 
which the fragments of tissue still retain some structural integrity so 
that the relationship between the nerve endings and associated cells is 
largely unchanged. The chopping process increases the surface area of 
the tissue for the uptake of radiolabelled transmitters and precursors, 
allows a greater proportion of released transmitters to diffuse into the 
incubation medium and increases the accessibility of the receptor sites 
for drugs.
141
Tissue cubes of the nucleus accumbens were found to be largely undamaged 
by the 30 minute incubation and repeated centrifugation involved in the 
loading of the tissue with (h)-dopamine or (H)-choline, as indicated by 
the similarity between the rates of oxygen uptake before and after 
incubation and washing and the K***-stimulation of oxygen uptake. (Table 8) . 
The basal levels of oxygen uptake observed were about one eighth of those 
observed by Mcllwain and Buddie (1952) in tissue cubes of rat cerebral 
cortex chopped at 0.2 x 0.2 mm. Although compared with these findings
for this region the rate of oxygen uptake observed in the nucleus accumbens
o
appears very low, a possible indication of tissue damage during chopping, 
the observation of a K -stimulation of similar magnitude before and after 
incubation and washing indicates that the preparation sustained little 
further damage in this process.
Addition of 50mM-KGl to the incubation medium stimulated the release of 
(^H)-dopamine, (^H)-acetylcholine and (^H)-choline from tissue cubes of 
rat nucleus accumbens, striatum and septum.
A tissue cube preparation of striatum was tested for the Ga -ion
dependence of the KGl stimulation, (Figure 22), and was found to be
24* 4“
sensitive to the presence of Ga . High extracellular K concentrations
are thought to depolarise neuronal membranes in a manner similar to an
24*action potential in which an influx of Ga ions is necessary in the
transduction of the depolarisation into the release of neurotransmitter
from vesicular stores in the nerve ending. This process is termed
2*^"stimulus-secretion coupling". Although Ga is involved in this
24^ 24"process in-vivo, other divalent cations, e.g. Ba and Sr but not 
2+Mg , have been found to support the release of some neurotransmitters 
in-vitro (Cotman et al. 19?6) . M g ^  ions do not couple stimuli to 
secretion and inhibit the effects of Ga and the other ions when 
present in similar concentrations, indicating that these ions compete
±4%
either for a cell-membrane ionophore or for a site in the "coupling 
mechanism" within the nerve ending. The actual mechanism by which the
24-
influx of Ga into the nerve ending couples stimulus to secretion is as 
yet unresolved but a number of hypotheses have been proposed.
These include:
Ga chelation by negatively charged lipids on the inner surface of the
cell membrane and/or outer surface of the vesicular membranes, increasing
the frequency of membrane fusion by reducing mutual repulsion;
2+
Ga -induced decrease in cytoplasmic viscosity leading to an increased 
frequency of collisions between the vesicles and the cell membrane; and
O-J-
the involvement of actin and myosin-like proteins with Ga -binding sites 
equivalent to troponin-G which, when activated, physically pull vesicles 
into fusion proximity with the cell membrane (Maddrell and Nordmann,
1979).
4"
The effects of high extracellular K -ion concentrations in stimulating
release may not be identical to those of an action potential or
electrically-induced depolarisation, Arbilla and Langer (l9?8) reported 
4" 2
that 40mM-K stimulated ( h)-dopamine release from slices of rat
2 4 -
striatum by up to 40^ in the absence of Ga ions. In this study an 
approximately 19^ stimulation of release was observed in the absence of 
Ga^ (Figure 22) . 0 'Fallon et al (l98l) suggested that the Ga^
independent component of release came from the cytoplasmic "pool" of
4* 4“ 4"
neurotransmitter, mediated by K -inhibition of the Na ,K -ATPase,
These workers found that 20 |jM-ouabain, a specific inhibitor of the
Na ,K -ATPase, also stimulated (^H)-dopamine release from tissue cubes
of rat striatum without a depolarisation effect.
4”
50mM-K on its own was only found to cause the release of a small 
fraction of the total releasable pool of (^H)-dopamine, as confirmed by 
the effect of ImM-tyramine (Figure 19), which displaces catecholamines 
from all storage pools within the tissue, of which the vesicular stores
are only a small part (Javoy and Glowinski, 1971).
The relative integrity of the tissue cube preparation, while allowing
intercellular interactions to occur, is disadvantageous with respect to
the penetration of drugs to receptor sites not on the surface of the
fragments, and metabolism of drugs by enzymes present in the preparation.
High concentrations of drug have to be used to overcome these problems,
—4 -310 -10 -^ M-TRH was found to be necessary for noticeable stimulation of
3  4the release of (-^H)-dopamine. Sharp et al (198I) found that 10” M-TRH
was required to stimulate release of endogenous dopamine from tissue
cubes of nucleus accumbens 3%) and septum (csi 33%) •
To reduce the possibility of degradation of TRH by the tissue cube
preparations, all the media used contained the peptide antibiotic
Bacitracin,
McKelvy et al (l9?6) reported that Bacitracin (1,7 x 10”^M) completely 
inhibited TRH peptidase activity in guinea-pig brain subcellular 
fractions, Knisatschek and Bauer (1979) and Bauer and Nowak (1979) 
found that lOmM-Bacitracin inhibited by 63% the TRH aminopeptidase from 
porcine serum whereas 10”%-Bacitracin inhibited by 35% the TRH amidase 
from bovine anterior pituitary. More recently, Busby et al (1982) ■ 
reported that as much as 20mM-Bacitracin was required to inhibit 
pyroglutamate aminopeptidase and proline endopeptidase (TRH amidase) in 
rat brain homogenates.. These workers suggest that the effects of 
Bacitracin are non-specific but do not explain wby other workers have 
reported inhibition of TRH degradation over a range of lower concentrations 
of Bacitracin.
In this study 1,7 x 10 ^-Bacitracin was added to all the media used 
because this was the concentration used by Kerwin and Pycock (1979), 
who reported stimulation of release of (^H)-dopamine from tissue cubes 
of rat nucleus accumbens (up to 100^) with 25 - 100 jjM-TRH.
The tissue-cube preparation, therefore was found to be viable with 
respect to the study of neurotransmitter release and the limitations 
in its use were taken into account.
4.2c) P2 preparations
P2 preparations may be regarded as refined tissue homogenates in which 
a sub-population of tissue fragments, the nerve-ending particles, are 
selectively concentrated. The method used for P2 preparation was the 
same as that used by Shapiro (1978). No density-gradient centrifugation 
was used to purify further the nerve-ending particles so the P2 suspension 
also contained fragments of myelin, non-synaptosomal vesicles and 
mitochondria. This was confirmed by electron micrography (Figures 23, 24 
and 25)i which also revealed the presence of relatively highly stained 
particles, containing subcellular vesicles and mitochondria, some 
associated with post-synaptic membranes. The high percentage (>70%) 
of the lactate dehydrogenase occluded by the preparations in all cases 
confirmed that the preparations contained a high proportion of sealed 
subcellular particles.
50mM-KGl stimulated the release of (^H)-dopamine from P2 preparations.
2+
A P2 preparation of striatum was found to exhibit Ga sensitivity to
50mM-KGl stimulated release of (^ H) -dopamine (Figure 27) , suggesthig'-fchat
release by stimulus-secretion coupling was taking place,although the 
24-
effect of Ga was not as marked as that in the tissue cube preparation.
2+ 4-
A Ga -independent K -stimulated release of about 4l^ was observed,
P2 preparations provide a simplified system for the study of 
neurotransmitter biochemistry because there are no diffusional barriers 
for drugs and released neurotransmitters can diffuse quickly into the 
Incubation medium. An additional advantage is that washed or purified 
P2 preparations do not degrade TRH (Parker et al, 1977; Shapiro et al 
1980; Biggins et al, 1981;) unless the preparation is subjected to 
lysis of vesicles and the release of cytoplasmic enzymes (Griffiths 
et al 1980),
iH-:?
One disadvantage is that, as synaptosomes are isolated from one another, 
these preparations only allow the study of direct drug-receptor 
interactions. Indirect effects of a drug on neurotransmitter 
biochemistry cannot be observed without a greater structural integrity.
The concentration of TRH used (lO ^M) was the same as that used by 
Shapiro et al (I98O) and the effects on (%)-dopamine release were 
similar to those observed in the tissue cube preparation, suggesting 
that lack of diffusion to receptors is not the limiting factor in the 
releasing effects of TRH.
In conclusion, although both tissue cube and P2-preparations were 
found to be viable with respect to uptake and release of (^H)-dopamine, 
exhibiting stimulus-secretion coupled release, the tissue-cube 
preparation appeared to be the better of the two in these respects. 
Moreover, tissue cubes were more easily and rapidly prepared than were 
P2 preparations, with fewer preparatory stages being involved. In general, 
basal release from tissue cubes was lower than that from P2 preparations, 
reducing the background over which the small effects of TRH and its 
analogues had to be observed.
Tissue cubes appeared to be the more convenient preparation with which 
to study the effects of TRH on the release of neurotransmitters,
4 .3  Release Assays 
4.3a) Filtration
The filtration assay was similar to that used by Raiteri et al (1974) 
except that positive pressure instead of negative pressure was used to 
separate the incubation medium from the tissue. The apparatus used was 
very similar to that used by Haycock and Meligeni (1977)• This type of 
assay provides a convenient method of pre-loading, washing and 
stimulating release without excessive physical manipulation of the tissue.
However, as this is a static incubation technique, problems arise 
when studying the release of catecholamines due to their rapid 
reuptake by the tissue.
To eliminate the problem of reuptake, and replace metabolised TRH, the 
perfusion assay was tried,
4.3b) Perfusion
This technique was essentially similar to those of Srinivasan et al 
(1969), Mcllwain and Snyder (l9?0), Raiteri et al (1978), Kerwin and 
Pycock (1979)1 Kamal et al (198O) and 0'Fallon et al (198I),
One advantage of perfusion is that it allows tissue to be conveniently 
washed without excessive manipulation.
With this technique time-courses of release may be followed easily and 
tissue preparations can be treated consecutively with different media, 
e.g., a single batch of tissue cubes could be treated with TRH, the 
TRH washed out and then treated with 50mM-KGl to assess the viability 
of that preparation.
In addition to the advantages of perfusion, the technique had a number 
of disadvantages, namely:
tissue cubes tended to clump together on the filters.
This led to irregularities of flow within the perfusion chamber, 
possible non-uniform exposure of the tissue to the TRH and therefore 
to erratic levels of basal release and stimulation; the technique was 
wasteful of reagents. Large volumes of TRH solutions had to be prepared 
for each assay; and
replicate incubations were not found to be easily performed on a single 
batch of tissue.
Upward perfusion was tried to eliminate the clumping of the tissue on 
the filters but the tissue cubes were found to either sink into the 
inlet tube or be forced into the outlet.
±4/
The static assay terminated by centrifugation was tried as an 
alternative to filtration and perfusion,
4.3c) Centrifugation terminated assay
The technique was similar to that used by Eitan and Herschkowitz (1977) 
and Shapiro et al (1980), except that it was applied to tissue-cube 
preparations as well as to P2 preparations.
Despite the fact that this is another static technique with the 
associated problems of reuptake of (^H)-dopamine, there were a number 
of advantages of this technique, namely:
sufficient replication could be carried out to allow statistical 
evaluation of the results of a single experiment;
each assay was self-contained, i.e. the amount of radioactivity found 
in the supernatant in any tube could be directly related to that 
remaining in the tissue in that tube and absolute GPM released could 
be related to the quantity of tissue in each tube; and release could be 
terminated rapidly by cooling and immediate centrifugation.
The tissue was vortexed continually over the period of the assay in an 
attempt to increase the diffusion of released neurotransmitter into the 
incubation medium and so to reduce the extent of reuptake of (^H)- 
dopamlne. This assay was also used for the release of (^H)-acetylcholine 
and (^H)-choline, where reuptake would not interfere with the results 
obtained.
The centrifugation-terminated assay was the one most used in this study,
4.4 Discussion of Results 
4.4a) Release of dopamine
l) Filtration
~310 M TRH in the filtration assay produced a variable effect on the 
release of (^H)—dopamine from nucleus accumbens tissue cubes, ranging 
from no stimulation to 33% stimulation relative to the controls,
I aM
This variation was probably due to a combination of the drawbacks of 
this assay and lack of uniform penetration of the TRH, These results 
prompted the change to the perfusion assay.
2)Perfusion
The medium for this assay was changed from the HEPES buffered saline 
of Dayton et al (1979)i which was used in the filtration assay, to the 
TRIS buffered saline used previously by Shapiro (1978) and Shapiro 
et al (1980).
Shapiro (1978) reported that TRH (10”^ M) stimulated dopamine release 
from rat striatal P2 preparations to a, greater extent at pH 6,5 
compared with pH 7.4. This study supported this observation in tissue 
cubes of nucleus accumbens since 5 % 10~^M TRH had little or no effect 
on the release of (^H)-dopamine at pH 7.4 whereas at pH 6,5 this 
concentration of peptide caused a small (approximately 20^) stimulation 
of release. One explanation for this pH effect may be that the optimum 
pH for TRH inactivation by TRH amidase, isolated from rat hypothalamus, 
is pH 7.38 and that this activity falls off sharply on either side of 
the optimum so that at pH 6,5 it is only about 40% that at pH 7«38 
(Griffiths et al, 198O),
A second possibility is the effect of pH on the ionisation of the 
histidine residue in the TRH molecule. At pH 7.4 this group is only 
28% ionised whereas at pH6.5 it is 78% ionised. If the TRH receptor 
has a greater affinity for the ionised histidine residue than for the 
unionised residue then the effects of TRH will be seen more clearly at 
pH values below 7.0, Kerwin and Pycock (1979) observed TRH-stimulated 
(^H)-dopamine release ( —  100%) at pH 7.4 but did not look for a pH 
effect on this release.
At pH6,5 the buffering capacity of TRIS (pKa = 8,6) is very low so in 
an attempt to study the effects of pH on TRH-stimulated release and 
retain a good buffering capacity, the TRIS in the perfusing medium was 
changed for an equimolar concentration of imidazole (pKa = 7.0).
No stimulation of (^H)-dopamine release ty 5 x 10 TRH was observed 
when TRIS was replaced by imidazole at either pH 6.5 or pH 7.4. In 
view of the similarity between histidine and the imidazole in the 
saline, it would seem possible that imidazole could act as an antagonist 
of TRH receptors, particularly since the ratio of imidazole to TRH was 
400:1. The competition of imidazole with TRH was not pursued further 
because it was necessary to try and establish a definite effect of TRH 
on dopamine release before studying the influence of TRH-inhibitors on 
that effect.
Variable results were obtained when the TRIS saline was replaced by 
HEPES saline, ranging from inhibition, through no effect, to stimulation 
of the releaseof (^H)-dopamine by 5 % 10"\l TRH. There is little 
similarity between HEPES and any part of the TRH molecule (Figure 28 ) 
so the reason(s) for the lack of consistency of TRH in this saline 
remains unclear. Since assays using HEPES buffered saline produced 
such variable results, the use of this saline was discontinued and TRIS 
buffered saline was used in all subsequent assays.
3)Centrifugation-terminated release in tissue cubes
The results obtained using this technique were qualitatively similar to 
those obtained using the perfusion technique, viz; no clear effect of 
TRH (lO ^  - 10 ^ )  on the release of (^H)-dopamine at pH 7.4 but an 
apparent concentration dependent stimulation of release of up to 45% 
with 10”&  TRH at pH 6.5.
The analogue GG3703 (lO” -10 M) appeared to stimulate release in a 
concentration dependent manner at pH 6,5 but not at pH 7.4, but its 
effects were less marked than those of TRH (up to 28%).
Figure 28 Comparison of the structures of compounds used in "buffered 
salines with the structure of TRH,
N H -
H O H 2 C  C  C H ^ O H
C H ^ O H
2 - a m i n o - 2 - h y d  roxymechy I propane? 
, 1, 3 - d i o l  (T R IS )
HOHjCH^CN
N CHjCHjSOjH
N - 2 - h y d  ro xyethy  I p iperazine-  
N - 2 - e t h a n e  sulphonic acid 
(H E P E S )
_l m i d a z o l e
T R H
O
N H
H
±D1
This study provides no evidence that GG3703 is more potent than TRH 
in stimulating the release of (^H)-dopamine "but gives no indication
of whether or not the effects of CG3703 outlive those of TRH due to an
increased biological half-life, as Flohe et al (198I) advocate.
However, this study does support the pharmacological studies of Hennies 
et al (1981), who suggested that GG3703 interacts with dopaminergic 
neurones.
Centrifugation terminated release in P2 preparations 
This study supports the results of Shapiro et al (1980) in that 
10”^M TRH stimulated the release of (^H)-dopamine from striatal P2 
preparations to a greater extent at pH 6.5 compared with pH 7*^*
Nevertheless, TRH had only at best a slight and variable stimulâtozy
effect on (^H)-dopamine release from striatal P2 preparations, (4-88^).
In nucleus accumbens P2 preparations a more consistent stimulation of 
release ty 10"^M TRH was observed, at pH 6.5 (9-3^^) but not at pH 7.4.
This agreed with the results of the tissue cube experiments.
The metabolite of TRH, histidylproline diketopiperazine (cyclo His Pro,
10 ,), proposed by Prasad et al (1977) to be a more active form of
TRH in some behavioural studies, also appeared to stimulate the 
release of (^H)-dopamine from P2 preparations of nucleus accumbens 
(15-42^) and striatum (13-91%) at pH 6,5 but its effects were not 
markedly greater than those of TRH in the nucleus accumbens and were 
no less variable in the striatum. An effect of cyclo His Pro but not 
TRH in P2 preparations would have implied that TRH underwent processing 
in tissue cubes to the cyclic dipeptide, which then stimulated the 
release of dopamine. The results obtained indicate that this does not 
occur, or at least that if processing to cyclo His Pro does occur then 
TRH receptors will accept it and TRH equally well. The increased potency 
of cyclo His Pro over TRH which has been observed in-vivo may be consequence 
of the deactivation of TRH by deamidation, which the cyclic dipeptide does 
not undergo.
' In general, the work on TRH-.dopamine interactions presented in this 
thesis is in agreement with the findings of other workers (Kerwin and 
Pycock, 1979)1 that ÏRH and its analogues stimulate the release of 
(^H)-dopamine from tissue preparations of rat nucleus accumbens.
The findings also agree with those of Shapiro et al (198O) in that the 
effects observed are dependent in magnitude on pH. TRH was not observed 
to stimulate consistently the release of (^I^dopamine from P2 
preparations of nucleus accumbens or striatum at pH 7.4 whereas 
Shapiro (1978) found a consistent stimulation of release at pH 7.2 
(15-59%) and a larger stimulation at pH 6.6 (l49%) from striatal P2 
preparations.
The requirement for high concentrations of TRH ( ^  lO""^) to produce 
a slight stimulation of (^H)-dopamine release agrees with the findings 
of Sharp et al (l98l), who found high concentrations of TRH to be 
necessary to stimulate release of endogenous dopamine.
In view of evidence implicating TRH in cholinergic processes 
(Section 1.3.3b l) and the reported effects of acetylcholine on 
dopamine release (banger, 1974; Griorguieff et al, 1975» de Belleroche 
and Bradford, 1978; de Belleroche and Gardiner, I982), it seemed 
reasonable to study the effects of TRH and its analogues on 
acetylcholine release in the regions of rat brain best correlated 
to its behavioural effects, i.e. the nucleus accumbens and the septum.
4.4b) Release of acetylcholine
Acetylcholine (AGh) is not a convenient substance to assay directly 
and most methods apart from bioassay entail hydrolysis by 
acetylcholinesterase followed by further reactions yielding a substance 
which can be more easily determined, e.g.
+ (a)
CÏLCO. OCMg CEgB.( CE ) . _______________ ^  CH^CO^H
+ %2°
+
HOOHgOHgMfCH )
(b)*1* 4"
HOGHgCH^N(GH^)^ + —— -------------==^ ^^OGHgGH^N(GH^)^
+ ADP + HgO
(a) = acetylcholinesterase (S.G.3.1.1.7)
(b) = choline kinase (E.G.2.7.1.32)
Oholine-^^P-phosphate is passed down a cation exchange column, which 
retains residual AT^^, and is estimated try liquid scintillation counting 
(Gooper et al, 1978).
o "14
It is more convenient to measure directly the release of ( H) or ( G)-AGh 
although the relationship between the release of radiolabel as a percentage 
of the total radioactivity in the tissue and the release of endogenous AGh 
from the total releasable pool cannot be readily determined.
An additional complication with AGh is that tissue cannot be directly 
pre-loaded with ( H)-AGh because choline (Gh), not AGh, is taken up by 
the tissue and is subsequently acetylated (Cooper et al 1978).
In order to assay AGh specifically, it must be separated from Gh. In release 
assays such as those used in this study a great dilution takes place when 
the neurotransmitter is released into the incubation medium so the AGh and Gh 
in the medium must first be concentrated.
Fonnum (1969) used a form of liquid ion exchange with a "resin" consisting 
of sodium tetraphenylboron in butylethyIketone. The extraction of 
acetylcholine and choline followed the following scheme;
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a)Forniation of an organic-soluble complex:
+ + //y---
 ^Na +(CH^)gNOHgCHgO .OGOHg mCH,OH^O.OCCH^
X- ^  ^  . ^ (“ 3 )3
Organic Aqueous Organic
"f" M
+NaX” Aqueous
b) Separation of the organic and aqueous layers
c)Breaking of the organic complex with Ag^ions:
NGH„GH„O.OGGH
( ^ 3)3
+
+
(GH^^GH^GH^O.OGGH,GH^GOgAg
+
CH^GOg'
Marohbanks and Israel (1971) added a washing step with diethyl ether to 
remove contaminating tetraphenylboron and acidification to remove excess 
silver acetate.
d)Separation of water layer and evaporation to dryness in a desiccator.
The extracted acetylcholine was redissolved in a small volume of methanol 
containing choline and acetylcholine as markers for the separation on 
cellulose TLG,
This technique is sensitive to the organic solvent used, Fonnum (I969) 
found the best solvents to be vinylacetonitrile or butyl ethyl ketone/ 
acetonitrile (5 : 1 v/v), which extracted about 90^ of the AGh from the
aqueous phase.
The volatile and toxic solvents used in this technique require the 
extraction to he performed in the fume cupboard and care must be taken 
in separating the organic and aqueous layers to prevent an emulsion 
forming on the interface. (Marchbanks and Israel, 19?l).
In this study, (^H)AGh and (^H)Gh in the medium were concentrated by 
freeze-drying and re-dissolved in a small volume of methanol containing 
AGh and Gh as markers for the separation on cellulose TLG plates.
This process was simpler and non-toxic compared with the organic 
extraction, was not found to hydrolyse the AGh and also gavec^ 90^ 
recovery of AGh (Table 24 .^
The Rp values obtained on cellulose TLG in butan-l-ol/water/ethanol/ 
glacial acetic acid solvent (O.43 for AGh, 0,33 for Gh) were lower than 
those reported by Marchbanks and Israel (l9?l), who found 0.56 for AGh 
and 0,45 for Gh, but were found to be consistent between experiments 
(Figure 15).
Using the TLG separation, tissue cubes of nucleus accumbens and septum
were shown to acetylate ( H)-Gh to ( H)-AGh, It was, however, found
that 40-70^ of the (^H)-Gh in the tissue was left unacetylated.
These percentages seem rather high considering that the concentration
of Gh added (0,17 |jM final concentration) was well below the Km of the
high affinity choline uptake mechanism (Km = 1.2 jjM ; Yaraamura and
Snyder, 1972), which is tightly coupled to AGh synthesis (Cooper et al,
1978). Yamamura and Snyder (1972) reported an inverse relationship
between the concentration of Gh incubated with cortical synaptosomes 
and conversion of Gh to AGh, .
Conversion was about l6^ with 10” M Gh and about 70^ with 5 x 10” M Gh 
after 15 minutes of incubation. This suggests that in this study 
substantial amounts of (^H)-Gh were still adsorbed to the surface of 
the tissue even after successive washes.
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The k "^ -stimulât!on of release of (^H)-Gh as well as (^H)-AGh from tissue 
cubes of both nucleus accumbens and septum is at variance with reports 
on AGh release from both tissue slice (Richter and Marchbanks, 1971;
Mulder et al, 1974) and P2 preparations (Wonnacott and Marchbanks, 1976; 
Muirrin, 1977, Wonnacott, 1980, Marchbanks et al, 1981). The 
stimulation of (^H)-Gh release observed in 50mM-KGl may therefore be 
due to displacement of the (^H)-Gh adsorbed to the tissue by the increased 
K^-ion concentration in the medium.
The K -induced stimulation of (-^ H) -AGh release {200—500^ over 5 minutes) 
was similar to that observed by other workers (Wonnacott (l980)
188^ in 20 minutes; Wonnacott and Marchbanks (1976) ; 450%;
Richter and Marchbanks (l97l) : 560%; Mulder et al (1974) :
700% in 10 minutes),
Neither TRH (10"”^ M) nor its analogues cyclo His Pro (lO"%) and 
GG3703 (10~^M) were found to have any significant effect on the release 
of (^H)-Ach from tissue cubes of nucleus accumbens or septum under 
basal or depolarising conditions. The most consistent effect observed 
was that of mild inhibition by cyclo His Pro of basal (^H)-AGh release 
from tissue cubes of septum in which most (4/5) of the preparations 
responded in this way. The third preparation, however, responded to 
10 ^M cyclo His Pro with a stimulation of (^H)-AGh release as large 
as the greatest inhibition observed.
This study provides no evidence that the effects of TRH in rats which 
appear to arise from some interactions with cholinergic neurones 
originate in either the nucleus accumbens or septum. The lesioning 
studies of Kalivas et al (198I) suggest that the sensitivity of the 
septum in behavioural paradigms may be due to effects of TRH on nerve 
fibres passing through that region, synapsing in some presently 
unidentified brain region.
Malthe-S/renssen et al (1978) observed that TRH (2Bnmol, l.c.v.) 
reduced the AGh content and stimulated AGh turnover of rat parietal 
cortex, but had no effect on the AGh content or turnover of frontal 
cortex, striatum, hippocampus, diencephalon or brainstem. Rat parietal 
cortex contains high affinity TRH receptors in the same concentration 
as those in the septum (9,2 - 0.9 f mol/mg protein for parietal cortex,
9,1 - 0.6 f mol/mg protein for septum) (Taylor and Burt, 1982) so this 
region may be a contender for the site of the actions of TRH on 
cholinergic processes.
The recent finding that, in the rat, the amygdala has the highest 
concentration of high affinity TRH receptors of any brain region 
(Taylor and Burt, 1982) has opened the question of whether or not any 
of the behavioural effects of TRH may be mediated by this region. The 
amygdala, also, is rich in cholinergic nerve fibres (jacobowitz and 
PalkarvitSp 1974) .
4,5 Effects of peptides other than TRH on neurotransmitter biochemistry 
The reported effects of TRH on neurotransmitter biochemistry must be 
discussed in context with those of other neuroactive peptides so that 
the importance of these effects may be kept in perspective. The effects 
of other peptides are outlined below:
4.5a) Endorphins
The effects of jÔ-endorphin on in-vitro tissue preparations have been 
studied in a number of laboratories,
Loh et al (1976) reported that ^  - endorphin (0,6 - 3,0 pM) inhibited 
the release of (^H)-dopamine from rat striatal slices by up to 99^ 
(p-<0.G2). This effect was found to be 18-33% greater than that 
produced by 3.0 pM-morphine and was reversed by 3.0 pM-naloxone 
(p <  0,0l). The pentapeptide methionine-enkephalin (met^-enkephalin), 
which has the same structure as the first five amino acids of ^ -endorphin, 
did not inhibit striatal dopamine release in concentrations as high as 
100 pM.
±DO
Izumi et al (197?) reported that injections of^-endorphin (l5 nmol i.c.v.) 
into rats reduced slightly (— 10%) the depletion of dopamine in the 
striatum following oC-methyltyrosine administration, suggesting an 
inhibition of dopamine release,
Arbilla and Langer (1978) observed that the release of (^H)-
noradrenaline from tissue slices of rat cerebral cortex was inhibited
by 50% by 0,6 pM ^  -endorphin (pCO.OOl). 10 pM-morphine was required
O
to inhibit (H)-noradrenaline release by the same extent. The 
inhibitory effects of both p-endorphin and morphine were inhibited by 
3 pM-naloxone (p<0.005) . These workers found no effect of ^  -endorphin 
(2 pM) or moiphine (30pM) on 20mM-KGl stimulated (^H)-dopamine release
from tissue slices of rat striatum.
Wilkes and Yen (1980) reported that -endorphin (0.5 nmol) inhibited 
the release of dopamine (DA) and dihydroxyph enylac et ic acid (DOPAG), by 
68-71% and 49-55% (p«c0 .05) respectively, from rat medial basal 
hypothalamus. Naloxone (0.5 nmol) stimulated DA release by 85-132% 
and DOPAG release by 120-148% (p<0,05). When administered together 
(0,5 nmol), yS -endorphin and naloxone had no effect on DA or DOPAG 
release,
Schoemaker and Nickolson (198O) reported that des-tyr^-)^-endorphin 
(amino acids 2-17 of^-endorphin) (0 .06 pM) depressed K^-evoked release 
of (^H)-dopamine from rat striatum, nucleus accumbens and frontal 
cortex by almost 20% (p<C0,02), without affecting basal (^H)-dopamine 
release.
These findings suggest that^-endorphin and its derivatives have potent 
inhibitory effects on the release of dopamine and noradrenaline which 
are probably elicited by presynaptic interactions with opiate receptors.
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4,5b) Melanostatin (Melanocyte stimulating hormone release inhibiting factor, MIF 
Friedman et al (1973) observed that MIF (l.O and 4-.0 mg/kg i.p.) 
administered chronically to rats for four days increased significantly 
(17% and 25% respectively, p<O.Ol) striatal dopamine content but not 
hypothalamic noradrenaline content, relative to that in animals given 
the saline vehicle alone.
Acute doses of up to 5 mg/kg i.p. had no effect on the levels of either 
catecholamine.
Shapiro et al (198O) found that MIF (lO”^M) stimulated the release of 
( H)-dopamine from P2 preparations of rat striatum by 14-48% at pH 7.2 
(p<0.05) and by 85% at pH 6.6 (p<0.05) in the presence of 1,25 mM-GaGl^. 
In the presence of 2mM-EDTA, 10~^M MIF inhibited (^H)-dopamine release 
7% at pH 7 .2 and 31-51% (p<0.05) at pH 6,6,
4.5c) Other peptides
Malthe-S/renssen et al (1978) observed that i.c.v, injections of 
neurotensin (6 nmol), angiotensin II (4,8 nmol) and somatostatin 
(6.1 nmol) reduced the AGh content of rat parietal cortex 33%, 39% and 
28% respectively (p<O.Ol) without affecting Gh content.
The same doses of neurotensin and somatostatin stimulated AGh turnover 
in the diencephalon by about 71% (pcO.Ol). Somatostatin (6.1 nmol i.c.v,) 
stimulated AGh turnover in the brainstem by 139% (p<0,0l). Higher doses 
of somatostatin, (15-21 nmol i.c.v.) stimulated AGh turnover in the 
hippocampus by 108-l40% (p<0.005).
The effects of other peptides on neurotransmitter biochemistry, 
especially the inhibitory effects of endorphins on catecholamine 
release,appear to be greater than the reported stimulatory effects of 
TRH and require much lower peptide concentrations in-vitro. Tache 
et al (1977)I however, observed that the depression of motor activity 
in rats given^- endorphin (50 pg i.c.v.), about 40% (p<0.05) was 
completly reversed by TRH (lO jig i.c.v.), which stimulated motor
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activity by about 125% relative to the control (p-<0 .005) in the 
presence of ^-endorphin. In the absence of ^ -endorphin, TRH 
stimulated motor activity by about 100% relative to the control 
(p<=0.005) .
These findings suggest that the difference in potencies of TRH and 
-endorphin in-vitro may not necessarily indicate that TRH has less 
intrinsic biological activity but that the tissue preparations 
presently in use may be in some way unsuitable to exhibit the effects 
of TRH.
4.6 Summary to Discussion
TRH appears to stimulate to a small extent the release of (^H)-dopamine 
from tissue preparations of rat nucleus accumbens and striatum. This 
effect is more clearly seen at pH 6,5 than at pH 7.4 and is more 
consistent in the nucleus accumbens than in the striatum. The TRH 
analogues cyclo His Pro and GG3703 appear to have effects on the 
release of ( h)-dopamine similar to those of TRH. The reported 
increased potency of the latter two peptides in behavioural paradigms 
may therefore be due to resistance to degradation rather than to 
increased biological activity.
The effects of TRH on dopamine release in the nucleus accumbens appear 
to be direct and not mediated via cholinergic effects on dopamine 
release since TRH stimulates ( h )-dopamine release from P2 preparations, 
but not of AGh from tissue cubes,
TRH, cyclo His Pro and CG3703 have not been found to have any consistent 
effect on AGh or Gh release from tissue cubes of nucleus accumbens or 
septum. On this basis, the reported behavioural effects of TRH which 
appear to arise from interactions of the peptide with cholinergic 
processes do not appear to originate in the nucleus accumbens or septum 
per se, but may require the presence of neurones connecting these regions 
to presently unidentified sites of AGh release.
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Interactions of TRH with other peptides, e.g.^-endorphin, which have 
been found to inhibit dopaminergic activity, may consitute a fine 
control mechanism in the GNS.
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